id,pmid,year,seq,MAP,name,cter,nter,lyn_cyc,ldmix,non_nat,len,nature,activity,source,origin,exp_str,non_hem,dssp,smiles
1067,19799950,2010,SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK,SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK,SK84,Free,Free,Linear,L,None,84,Antimicrobial and Anticancer,0.01% Hemolysis at 100 µM,Mouse,SK84 (larvae of Drosophila virilis),NA,NA,CCCSCSSSSSSCGGGCTTSTTCSSSBSSSBSSSCHHHHHHHHHHHTTTGGGTTTSCTTCSGGGSCTTTTCCHHHHSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)O
1068,19799950,2010,SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK,SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK,SK84,Free,Free,Linear,L,None,84,Antimicrobial and Anticancer,0.01% Hemolysis at 100 µM,Human,SK84 (larvae of Drosophila virilis),NA,NA,CCCSCSSSSSSCGGGCTTSTTCSSSBSSSBSSSCHHHHHHHHHHHTTTGGGTTTSCTTCSGGGSCTTTTCCHHHHSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)O
2004,21928440,2011,CGETCVGGTCNTPGCTCSWPVCTRNGLPV,CGETCVGGTCNTPGCTCSWPVCTRNGLPV{cyc:N-C},Kalata B1,Free,Free,Cyclic,L,None,29,Anticancer and Anti-HIV,IC50 = 26 µM,Human,Kalata (Oldenlandia affinis),NA,NA,CCCGGGTTTSSCCCCCSSSCCCTTCSSCC,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)C(C)C
2005,21928440,2011,cgetcvggtcntpgctcswpvctrnglnpv,C{d}G{d}E{d}T{d}C{d}V{d}G{d}G{d}T{d}C{d}N{d}T{d}P{d}G{d}C{d}T{d}C{d}S{d}W{d}P{d}V{d}C{d}T{d}R{d}N{d}G{d}L{d}N{d}P{d}V{d}{cyc:N-C},D-Kalata B1,Free,Free,Cyclic,D,None,29,Anticancer and Anti-HIV,IC50 = 77 µM,Human,Kalata analog (Oldenlandia affinis),NA,NA,CCCSSSSCCCCCTTTTCCCCSSSSSCSCCC,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)C(C)C
2382,12147359,2002,AKKVFKRLEKLFSKIQNWK,AKKVFKRLEKLFSKIQNWK,Anal 1,Free,Free,Linear,L,None,19,Antibacterial and Antifungal and Anticancer,0% Hemolysis at 100 µM (non-hemolytic),Human,HP (2 – 20) analogs (Helicobacter pylori),NA,Non-hemolytic,CGGGGGGTGGGSCTTTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)O
2383,12147359,2002,AKKVFKRLEKLFSKIWNDK,AKKVFKRLEKLFSKIWNDK,Anal 2,Free,Free,Linear,L,None,19,Antibacterial and Antifungal and Anticancer,0% Hemolysis at 100 µM (non-hemolytic),Human,HP (2 – 20) analogs (Helicobacter pylori),NA,Non-hemolytic,CTTTTHHHHHHHCCSSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O
2384,12147359,2002,AKKVFKRLEKLFSKIWNWK,AKKVFKRLEKLFSKIWNWK,Anal 3,Free,Free,Linear,L,None,19,Antibacterial and Antifungal and Anticancer,0% Hemolysis at 100 µM (non-hemolytic),Human,HP (2 – 20) analogs (Helicobacter pylori),NA,Non-hemolytic,CGGGGHHHHHHHHHHSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)O
2385,12147359,2002,AKKVFKRLEKSFSKIQNDK,AKKVFKRLEKSFSKIQNDK,Anal 4,Free,Free,Linear,L,None,19,Antibacterial and Antifungal and Anticancer,0% Hemolysis at 100 µM (non-hemolytic),Human,HP (2 – 20) analogs (Helicobacter pylori),NA,Non-hemolytic,CHHHHTTGGGTTCTTSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O
2386,12147359,2002,AKKVSKRLEKLFSKIQNDK,AKKVSKRLEKLFSKIQNDK,Anal 5,Free,Free,Linear,L,None,19,Antibacterial and Antifungal and Anticancer,0% Hemolysis at 100 µM (non-hemolytic),Human,HP (2 – 20) analogs (Helicobacter pylori),NA,Non-hemolytic,CHHHHHHHHTTTCTTTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O
2514,10973820,2000,ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE,ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE,CRAMP,Free,Free,Linear,L,None,38,Antimicrobial and Anticancer,2.2% hemolytic at 100 µM,Human,"Derived from CRMAP, a member of cathelicidin-derived antimicrobial peptides",NA,NA,CCHHHHHTTTSTTHHHHHHHHHHTTGGGTHHHHSCCCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(C)C)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
2515,10973820,2000,GEKLKKIGQKIKNFFQKL,GEKLKKIGQKIKNFFQKL,CRAMP-18,Free,Free,Linear,L,None,18,Antimicrobial and Anticancer,0% hemolytic at 100 µM (non-hemolytic),Human,CRMAP,NA,Non-hemolytic,CCHHHHHHHHHHHHTTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC
2516,10973820,2000,GKKLKKIGQKIKNFFQKL,GKKLKKIGQKIKNFFQKL,K2-CRAMP-18,Free,Free,Linear,L,None,18,Antimicrobial and Anticancer,0% hemolytic at 100 µM (non-hemolytic),Human,CRMAP-18 analogs,NA,Non-hemolytic,CTTHHHHTTTHHHHTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC
2517,10973820,2000,GEKLKKIGKKIKNFFQKL,GEKLKKIGKKIKNFFQKL,K9-CRAMP-18,Free,Free,Linear,L,None,18,Antimicrobial and Anticancer,0% hemolytic at 100 µM (non-hemolytic),Human,CRMAP-18 analogs,NA,Non-hemolytic,CCSHHHHHHHHTTTTTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC
2518,10973820,2000,GEKLKKIGQKIKKFFQKL,GEKLKKIGQKIKKFFQKL,K13-CRAMP-18,Free,Free,Linear,L,None,18,Antimicrobial and Anticancer,0% hemolytic at 100 µM (non-hemolytic),Human,CRMAP-18 analogs,NA,Non-hemolytic,CCHHHHHHHHHHGGGGGC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC
2519,10973820,2000,GEKLKKIGQKIKNFFKKL,GEKLKKIGQKIKNFFKKL,K16-CRAMP-18,Free,Free,Linear,L,None,18,Antimicrobial and Anticancer,0.2% hemolytic at 100 µM,Human,CRMAP-18 analogs,NA,NA,CCSSTTHHHHHHHHCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC
2570,23609760,2013,FVDLKKIANIINSIFGK,FVDLKKIANIINSIFGK,Temporin-1CEa,Free,Free,Linear,L,None,17,"Antimicrobial, Anticancer and moderate Hemolytic",LC50 = 95.7 µM,Human,Temporin-1CEa (Rana chensinensis),NA,NA,CCCHHHHHHHHHHHTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
2571,23609760,2013,FVDLKKIANIINSIFKK,FVDLKKIANIINSIFKK,LK1,Free,Free,Linear,L,None,17,Anticancer,"LC50 = 1,467 µM",Human,Temporin-1CEa (Rana chensinensis),NA,NA,CCCHHHHHHHHHTTTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
2572,23609760,2013,FKDLKKIANIINSIFKK,FKDLKKIANIINSIFKK,LK2(5),Free,Free,Linear,L,None,17,Anticancer,"LC50 = 1,186 µM",Human,Temporin-1CEa (Rana chensinensis),NA,NA,CCCSIIIIIGGGTTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
2573,23609760,2013,FVKLKKIANIINSIFKK,FVKLKKIANIINSIFKK,LK2(6),Free,Free,Linear,L,None,17,Anticancer,"LC50 = 1,993 µM",Human,Temporin-1CEa (Rana chensinensis),NA,NA,CCCTHHHHHHIIIIICC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
2574,23609760,2013,FKKLKKIANIINSIFKK,FKKLKKIANIINSIFKK,LK3,Free,Free,Linear,L,None,17,Anticancer,"LC50 = 4,649 µM",Human,Defencin,NA,NA,CCGGGGHHHHHTTTTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
2575,23609760,2013,FVKLKKILNIINSIFKK,FVKLKKILNIINSIFKK,LK2(6)A(L),Free,Free,Linear,L,None,17,Anticancer,LC50 = 86.99 µM,Human,Temporin-1CEa (Rana chensinensis),NA,NA,CCSTHHHHHIIIIIICC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
2576,23609760,2013,FVKLKKILNIILSIFKK,FVKLKKILNIILSIFKK,LK2(6)AN(2L),Free,Free,Linear,L,None,17,Anticancer,LC50 = 28.34 µM,Human,Temporin-1CEa (Rana chensinensis),NA,NA,CCCTHHHHHHHHHHHHC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
2624,22869378,2013,kklallalkkwllalkklallalkk,K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}W{d}L{d}L{d}A{d}L{d}K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}{ct:Amid},D-LAK120,Amidation,Free,Linear,D,None,25,"Antimicrobial, Antiplasmodial and Anticancer",HC50 = 4.06±1.30 µM,Human,Synthetic peptide,NA,NA,CCCHHHHHHHHHHHHHHHHHHHHHC,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
2625,22869378,2013,kklallalkkwlpalkklallalkk,K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}W{d}L{d}P{d}A{d}L{d}K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}{ct:Amid},D-LAK120-P13,Amidation,Free,Linear,D,None,25,"Antimicrobial, Antiplasmodial and Anticancer",HC50 = 11.66±0.03 µM,Human,Synthetic peptide,NA,NA,CCSHHHHHHHHHHHHHHHHHHHTCC,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
2626,22869378,2013,kklalalakkwlalakklalalakk,K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}W{d}L{d}A{d}L{d}A{d}K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid},D-LAK120-A,Amidation,Free,Linear,D,None,25,"Antimicrobial, Antiplasmodial and Anticancer",HC50 = 17.42±2.17 µM,Human,Synthetic peptide,NA,NA,CHHHHHHHHHHHHHHHHHHHTGGGC,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
2627,22869378,2013,kklalalakkwlplakklalalakk,K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}W{d}L{d}P{d}L{d}A{d}K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid},D-LAK120-AP13,Amidation,Free,Linear,D,None,25,"Antimicrobial, Antiplasmodial and Anticancer",HC50 = 58.61±10.41 µMc,Human,Synthetic peptide,NA,NA,CHHHHHTGGGGHHHHHHHHHHHHHC,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
2628,22869378,2013,kklalhalkkwlhalkklahlalkk,K{d}K{d}L{d}A{d}L{d}H{d}A{d}L{d}K{d}K{d}W{d}L{d}H{d}A{d}L{d}K{d}K{d}L{d}A{d}H{d}L{d}A{d}L{d}K{d}K{d}{ct:Amid},D-LAK120-H,Amidation,Free,Linear,D,None,25,"Antimicrobial, Antiplasmodial and Anticancer",HC50 = 20.29±2.42 µM,Human,Synthetic peptide,NA,NA,CCSSSSHHHHCSHHHHCCGGGC,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
2629,22869378,2013,kkalahalkkwlpalkklahalakk,K{d}K{d}A{d}L{d}A{d}H{d}A{d}L{d}K{d}K{d}W{d}L{d}P{d}A{d}L{d}K{d}K{d}L{d}A{d}H{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid},D-LAK120-HP13,Amidation,Free,Linear,D,None,25,"Antimicrobial, Antiplasmodial and Anticancer",HC50 = 79.61±2.80 µM,Human,Synthetic peptide,NA,NA,CGGGSSSGGGHHHHHHHCSGGGC,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
2630,22869378,2013,kkalakalkhwlpalhklakalakk,K{d}K{d}A{d}L{d}A{d}K{d}A{d}L{d}K{d}H{d}W{d}L{d}P{d}A{d}L{d}H{d}K{d}L{d}A{d}K{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid},D-LAK80-HP13,Amidation,Free,Linear,D,None,25,"Antimicrobial, Antiplasmodial and Anticancer",HC50 = 8.61±0.35 µM,Human,Synthetic peptide,NA,NA,CHHHHHHHSSTTTCSCHHHHHHC,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
2631,22869378,2013,kkalkhalakwlpalkalahklakk,K{d}K{d}A{d}L{d}K{d}H{d}A{d}L{d}A{d}K{d}W{d}L{d}P{d}A{d}L{d}K{d}A{d}L{d}A{d}H{d}K{d}L{d}A{d}K{d}K{d}{ct:Amid},D-LAK160-HP13,Amidation,Free,Linear,D,None,25,"Antimicrobial, Antiplasmodial and Anticancer",HC50 = 185.0±18.65 µM,Human,Synthetic peptide,NA,NA,CTTTSCGGGTHHHHHHHSSSTTC,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
2634,22837667,2013,KWKSFLKTFKSLKKTVLHTLLKAISS,KWKSFLKTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid},P,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 5.20 ± 0.02μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2635,22837667,2013,KWKSFLkTFKSLKKTVLHTLLKAISS,KWKSFLK{d}TFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid},K7D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 10.4 ± 0.04μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2636,22837667,2013,KWKSFLKTFKSLKkTVLHTLLKAISS,KWKSFLKTFKSLKK{d}TVLHTLLKAISS{nt:Acet}{ct:Amid},K14D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 5.20 ± 0.02μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2637,22837667,2013,KWKSFLKTFKSLKKTVLHTLLkAISS,KWKSFLKTFKSLKKTVLHTLLK{d}AISS{nt:Acet}{ct:Amid},K22D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 20.81 ± 0.10 μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2638,22837667,2013,KWKSFLkTFKSLKkTVLHTLLKAISS,KWKSFLK{d}TFKSLKK{d}TVLHTLLKAISS{nt:Acet}{ct:Amid},K7D/K14 D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 20.81 ± 0.15μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2639,22837667,2013,KWKSFLKTFKSLKkTVLHTLLkAISS,KWKSFLKTFKSLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid},K14D/K22D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 20.81 ± 0.06μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2640,22837667,2013,KWKSFLkTFKSLKkTVLHTLLkAISS,KWKSFLK{d}TFKSLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid},K7D/K14D/K22D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 81.31 ± 0.17μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2641,22837667,2013,KWKSFLkTFkSLKkTVLHTLLkAISS,KWKSFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid},K7D/K10D/K14D/K22D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 325.20 ± 0.82μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2642,22837667,2013,KWkSFLkTFkSLKkTVLHTLLkAISS,KWK{d}SFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid},K3D/K7D/K10D/K14D/K22D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC >325.20μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2643,22837667,2013,kWkSFLkTFkSLKkTVLHTLLkAISS,K{d}WK{d}SFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid},K1D/K3D/K7D/K10D/K14D/K22D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC >325.20μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2644,22837667,2013,KWKSFlKTFKSLKKTVLHTLLKAISS,KWKSFL{d}KTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid},L6D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 10.40 ± 0.08μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2645,22837667,2013,KWKSFLKTFKSlKKTVLHTLLKAISS,KWKSFLKTFKSL{d}KKTVLHTLLKAISS{nt:Acet}{ct:Amid},L12D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 20.81 ± 0.03μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2646,22837667,2013,KWKSFLKTFKSLKKTVLHTlLKAISS,KWKSFLKTFKSLKKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid},L20D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 20.81 ± 0.13μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2647,22837667,2013,KWKSFlKTFKSlKKTVLHTLLKAISS,KWKSFL{d}KTFKSL{d}KKTVLHTLLKAISS{nt:Acet}{ct:Amid},L6D/L12D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 20.81 ± 0.10 μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2648,22837667,2013,KWKSFLKTFKSlKKTVLHTlLKAISS,KWKSFLKTFKSL{d}KKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid},L12D/L20D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 81.31 ± 0.43μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2649,22837667,2013,KWKSFlKTFKSlKKTVLHTlLKAISS,KWKSFL{d}KTFKSL{d}KKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid},L6D/L12D/L20D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 162.61 ± 0.19μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2650,22837667,2013,KWKSFlKTFKSlKKTVLHTlLKAISS,KWKSFL{d}KTFKSL{d}KKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid},L6D/L12D/L17D/L20D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC = 81.31 ± 1.05μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2651,22837667,2013,KWKSFlKTFKSlKKTVLHTllKAISS,KWKSFL{d}KTFKSL{d}KKTVLHTL{d}L{d}KAISS{nt:Acet}{ct:Amid},L6D/L12D/L17D/L20D/L21D,Amidation,Acetylation,Linear,Mix,None,26,Anticancer,MHC >325.20μmol/L,Human,Synthetic α-helical cationic anticancer peptides,NA,NA,CCGGGHHHHHHHTTSSSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
2916,21729875,2011,GKGRWLERIGKAGGIIIGGALDHL,GKGRWLERIGKAGGIIIGGALDHL{ct:Amid},NRC-01,Amidation,Free,Linear,L,None,24,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCCCTTTHHHHSSSCCCTTSSCC,CC[C@H](C)[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CN)[C@@H](C)CC)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)CC
2917,21729875,2011,WLRRIGKGVKIIGGAALDHL,WLRRIGKGVKIIGGAALDHL{ct:Amid},NRC-02,Amidation,Free,Linear,L,None,20,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CTTCCSSSCCCSSSSSSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)C(C)C
2918,21729875,2011,GRRKRKWLRRIGKGVKIIGGAALDHL,GRRKRKWLRRIGKGVKIIGGAALDHL{ct:Amid},NRC-03,Amidation,Free,Linear,L,None,26,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCCSCCCGGGCSCCSCCSSSSSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)C(C)C
2919,21729875,2011,GWGSFFKKAAHVGKHVGKAALTHYL,GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid},NRC-04,Amidation,Free,Linear,L,None,25,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCHHHHTTTCCCSSSSGGGSCC,CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)C(C)C)C(C)C)[C@@H](C)O)C(=O)O
2920,21729875,2011,FLGALIKGAIHGGRFIHGMIQNHH,FLGALIKGAIHGGRFIHGMIQNHH{ct:Amid},NRC-05,Amidation,Free,Linear,L,None,24,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CHHHHCCSSCSTTCCCTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O)[C@@H](C)CC)[C@@H](C)CC
2921,21729875,2011,GWGSIFKHGRHAAKHIGHAAVNHYL,GWGSIFKHGRHAAKHIGHAAVNHYL{ct:Amid},NRC-06,Amidation,Free,Linear,L,None,25,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCTTTSSCSSCCSSSCSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
2922,21729875,2011,RWGKWFKKATHVGKHVGKAALTAYL,RWGKWFKKATHVGKHVGKAALTAYL{ct:Amid},NRC-07,Amidation,Free,Linear,L,None,25,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCHHHHTTSSSSSCCTTSTTTCC,CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)O)C(C)C)C(C)C)[C@@H](C)O)C(=O)O
2923,21729875,2011,RSTEDIIKSISGGGFLNAMNA,RSTEDIIKSISGGGFLNAMNA{ct:Amid},NRC-08,Amidation,Free,Linear,L,None,21,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCTTHHHHTTSSCCCCTTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)O
2924,21729875,2011,FFRLLFHGVHHGGGYLNAA,FFRLLFHGVHHGGGYLNAA{ct:Amid},NRC-09,Amidation,Free,Linear,L,None,19,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CGGGTCSSSSSCCCCC,CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O
2925,21729875,2011,FFRLLFHGVHHVGKIKPRA,FFRLLFHGVHHVGKIKPRA{ct:Amid},NRC-10,Amidation,Free,Linear,L,None,19,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCCCCCSCSTTCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)O
2926,21729875,2011,GWKSVFRKAKKVGKTVGGLALDHYL,GWKSVFRKAKKVGKTVGGLALDHYL{ct:Amid},NRC-11,Amidation,Free,Linear,L,None,25,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCGGGHHHHCCCCCCSSSSCSCCC,CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)O
2927,21729875,2011,GWKKWFNRAKKVGKTVGGLAVDHYL,GWKKWFNRAKKVGKTVGGLAVDHYL{ct:Amid},NRC-12,Amidation,Free,Linear,L,None,25,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CGGGTHHHHGGGCSCCSSCSSCCC,CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)C(C)C)[C@@H](C)O)C(C)C)C(C)C)C(=O)O
2928,21729875,2011,GWRTLLKKAEVKTVGKLALKHYL,GWRTLLKKAEVKTVGKLALKHYL{ct:Amid},NRC-13,Amidation,Free,Linear,L,None,23,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CTHHHHTTTSTHHHHHHHTSCC,CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C(=O)O
2929,21729875,2011,AGWGSIFKHIFKAGKFIHGAIQAHND,AGWGSIFKHIFKAGKFIHGAIQAHND{ct:Amid},NRC-14,Amidation,Free,Linear,L,None,26,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCSCCTTCSCSSCCCCSTTCSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)O
2930,21729875,2011,GFWGKLFKLGLHGIGLLHLHL,GFWGKLFKLGLHGIGLLHLHL{ct:Amid},NRC-15,Amidation,Free,Linear,L,None,21,Anticancer,50% hemolytic at 64 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCTHHHHTTSSSTTCCCC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)O
2931,21729875,2011,GWKKWLRKGAKHLGQAAIK,GWKKWLRKGAKHLGQAAIK{ct:Amid},NRC-16,Amidation,Free,Linear,L,None,19,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CGGGTHHHHTCSSSSTTC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)O
2932,21729875,2011,GWKKWLRKGAKHLGQAAIKGLAS,GWKKWLRKGAKHLGQAAIKGLAS,NRC-17,Free,Free,Linear,L,None,23,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CHHHHGGGGGSCHHHHHTCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O
2933,21729875,2011,GWKKWFTKGERLSQRHFA,GWKKWFTKGERLSQRHFA,NRC-18,Free,Free,Linear,L,None,18,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCCCCCSCSSSCSCCCC,CC(C)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)O
2934,21729875,2011,FLGLLFHGVHHVGKWIHGLIHGHH,FLGLLFHGVHHVGKWIHGLIHGHH{ct:Amid},NRC-19,Amidation,Free,Linear,L,None,24,Anticancer,50% hemolytic at 16 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CTTSCCSSSTTTSCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O
2935,21729875,2011,GFLGILFHGVHHGRKKALHMNSERRS,GFLGILFHGVHHGRKKALHMNSERRS,NRC-20,Free,Free,Linear,L,None,26,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCCSSCCSSSCSSCCCCCCCCC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)O)C(C)C
2936,21729875,2011,GWKDWFRKAKKVGKTVGGLALNHYL,GWKDWFRKAKKVGKTVGGLALNHYL{ct:Amid},NRC-123,Amidation,Free,Linear,L,None,25,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CTHHHHHHHTTSCCTTTTCCSSCC,CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)C(C)C)[C@@H](C)O)C(C)C)C(=O)O
2937,21729875,2011,GIRKWFKKAAHVGKEVGKVALNACL,GIRKWFKKAAHVGKEVGKVALNACL,NRC-124,Free,Free,Linear,L,None,25,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CHHHHHHHHSSSTTTSTTCTTSCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C)C(C)C)C(C)C
2938,21729875,2011,GLKKWFKKAVHVGKKVGKVALNAYL,GLKKWFKKAVHVGKKVGKVALNAYL{ct:Amid},NRC-125,Amidation,Free,Linear,L,None,25,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)O
2939,21729875,2011,GWRKWIKKATHVGKHIGKAALDAYI,GWRKWIKKATHVGKHIGKAALDAYI{ct:Amid},NRC-126,Amidation,Free,Linear,L,None,25,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CHHHHTTTSSSSCSTTTTSCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)CC)C(=O)O
2940,21729875,2011,GCKKWFKKAAHVGKNVGKVALNAYL,GCKKWFKKAAHVGKNVGKVALNAYL{ct:Amid},NRC-127,Amidation,Free,Linear,L,None,25,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCTTTHHHHCCSCCSSSCCTTSCC,CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)CN)C(C)C)C(C)C)C(C)C)C(=O)O
2941,21729875,2011,GIRKWFKKAAHVGKKVGKVALNAYL,GIRKWFKKAAHVGKKVGKVALNAYL{ct:Amid},NRC-128,Amidation,Free,Linear,L,None,25,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CHHHHHHHHSSSTTTSSSCSSSCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C)C(C)C)C(C)C
2942,21729875,2011,GrrkrkWLrrIGkGVkIIGGAALDHL,GR{d}R{d}K{d}R{d}K{d}WLR{d}R{d}IGK{d}GVK{d}IIGGAALDHL{ct:Amid},NRC-03D,Amidation,Free,Linear,Mix,None,26,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)C(C)C
2943,21729875,2011,GRRKRKWLRRIGKGVKIIGGAALDHL,GRRKRKWLRRIGKGVKIIGGAALDHL{nt:Biotin}{ct:Amid},NRC-03B,Amidation,Biotin,Linear,L,None,26,Anticancer,50% hemolytic at >256 μg/ml,Human,Pleurocidin variant derived from gut and skin of pleuronectid flatfish,NA,NA,CCCSCCCGGGCSCCSCCSSSSSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)C(C)C
2944,21729875,2011,GIGKFLHSAKKFGKAFVGEIMNS,GIGKFLHSAKKFGKAFVGEIMNS{ct:Amid},Mag2,Amidation,Free,Linear,L,None,23,Anticancer,50% hemolytic at >256 μg/ml,Human,Magainin-2,NA,NA,CCSSSSSGGGTCSSGGGGTTTC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)O)[C@@H](C)CC)C(C)C
3252,23328867,2013,THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK,THRPPMWSPVWPGGGKLL{d}LKL{d}LK{d}K{d}LLKL{d}LKKK,TfR-lytic hybrid peptide,Free,Free,Linear,Mix,None,32,Anticancer,17% Hemolysis at 100 µM,Mouse,Synthetic peptide,NA,NA,CCTTSSSSSSCCCTHHHHHHHHHHHHHHHHC,CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C
4964,25123187,2014,KWKSFLKTFKSLKKTVLHTLLKAISS,KWKSFLKTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid},P(PNW),Amidation,Acetylation,Linear,L,None,26,Anticancer,MHC % Hemolysis at 10.41 ± 0.02 µM,Human,Peptide A12L/A20L,α-Helix,NA,CHHHHHHHHHHHTTTTSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
4965,25123187,2014,KIKSFLKTFKSWKKTVLHTLLKAISS,KIKSFLKTFKSWKKTVLHTLLKAISS{nt:Acet}{ct:Amid},PMW,Amidation,Acetylation,Linear,L,None,26,Anticancer,MHC % Hemolysis at 10.41 ± 0.01 µM,Human,Peptide A12L/A20L,α-Helix,NA,CHHHHTTHHHHHHHHHSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
4966,25123187,2014,KIKSFLKTFKSLKKTVLHTLLKAWSS,KIKSFLKTFKSLKKTVLHTLLKAWSS{nt:Acet}{ct:Amid},PCW,Amidation,Acetylation,Linear,L,None,26,Anticancer,MHC % Hemolysis at 10.41 ± 0.01 µM,Human,Peptide A12L/A20L,α-Helix,NA,CHHHHTTHHHHHHTTTSSHHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O
5469,26204061,2015,GIIKKIIKKIIKKI,GIIKKIIKKIIKKI{ct:Amid},FITC,Amidation,Free,Linear,L,None,14,Antibacterial and Anticancer,50 % Hemolysis at 256 µM,Human,Synthetic Amphiphiles,α-Helix,Low hemolytic,CGGGTSGGGTGGGC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(=O)O
5470,26204061,2015,IIKKIIKKIIKKI,IIKKIIKKIIKKI{ct:Amid},1,Amidation,Free,Linear,L,None,13,Antibacterial and Anticancer,50 % Hemolysis at 256 µM,Human,Synthetic Amphiphiles,α-Helix,Low hemolytic,CHHHHGGGTTTTC,CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
5471,26204061,2015,GIIKKIIKKIIKK,GIIKKIIKKIIKK{ct:Amid},2,Amidation,Free,Linear,L,None,13,Antibacterial and Anticancer,50 % Hemolysis at 500 µM,Human,Synthetic Amphiphiles,α-Helix,Low hemolytic,CTHHHHTHHHHTC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
5472,26204061,2015,IIKKIIKKIIKK,IIKKIIKKIIKK{ct:Amid},Rhodamine,Amidation,Free,Linear,L,None,12,Antibacterial and Anticancer,50 % Hemolysis at >1000 µM,Human,Synthetic Amphiphiles,α-Helix,Low hemolytic,CHHHHHHHHHHC,CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
5745,26100634,2015,GLFGVLAKVAAHVVPAIAEHF,GLFGVLAKVAAHVVPAIAEHF{ct:Amid},Maculatin 1.1,Amidation,Free,Linear,L,None,21,"Anticancer, Antibacterial Gram-",50 % Hemolysis at 29.5 ± 1.0 µM,Human,Australian Tree Frog Litoria Genimaculata,α-Helical,NA,CHHHHHHHHHSSSCTTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
5746,26100634,2015,GIGAVLKVTTGLPALISWIKRKRQQ,GIGAVLKVTTGLPALISWIKRKRQQ{ct:Amid},Melittin,Amidation,Free,Linear,L,None,26,"Anticancer, Antibacterial Gram-",50 % Hemolysis at 1.2± 0.1 µM,Human,Bee Venom,α-Helical,NA,CCCCCCCCCSSCHHHHHHHHTTCCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C
6227,27187467,2016,GMWSKIKETAMAAAKEAAKAAGKTISDMIKQ,GMWSKIKETAMAAAKEAAKAAGKTISDMIKQ{ct:Amid},Dermaseptin-PD-1,Amidation,Free,Linear,L,None,30,"Antibacterial, Antifungal, Anticancer",100 % Hemolysis at >156.8 µM,Horse,Pachymedusa Dacnicolor,α-Helix,Low hemolytic,CHHHHHHHHTTTTCTHHHHTTCCGGGGGTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCSC)NC(=O)CN)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)O
6228,27187467,2016,GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI,GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI{ct:Amid},Dermaseptin-PD-2,Amidation,Free,Linear,L,None,32,"Antibacterial, Antifungal, Anticancer",100 % Hemolysis at >161.6 µM,Horse,Pachymedusa Dacnicolor,α-Helix,Low hemolytic,CCGGGTSCCCCBSSSSSCCCSSSTTTSSBSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCSC)NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)O
6353,27129462,2016,RGSALTHLP,RGSALTHLP,RP9,Free,Free,Linear,L,None,9,"Antibacterial, Anticancer",3.3 ± 0.5 % Hemolysis at 61.2 µM,Human,Crocodile Leukocyte Extract,α-Helix,NA,CCCCCSCC,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)O)[C@@H](C)O
6354,27129462,2016,RGSALTHLP,RGSALTHLP,RP9,Free,Free,Linear,L,None,9,"Antibacterial, Anticancer",5.7 ± 0.2 % Hemolysis at 122.4 µM,Human,Crocodile Leukocyte Extract,α-Helix,NA,CCCCCSCC,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)O)[C@@H](C)O
6390,26952034,2016,ASKAGAIAGKIAKVALKAL,ASKAGAIAGKIAKVALKAL,XLAsp-P1,Free,Free,Linear,L,None,19,"Antibacterial, Anticancer",0 % Hemolysis at 8 μg/ml,Rabbit,Skin Of Xenopus Laevis,α-Helix,Low hemolytic,CCCCSCCSCCCTTTTTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C)[C@@H](C)CC
6391,26952034,2016,ASKAGAIAGKIAKVALKAL,ASKAGAIAGKIAKVALKAL,XLAsp-P2,Free,Free,Linear,L,None,19,"Antibacterial, Anticancer",0 % Hemolysis at 16 μg/ml,Rabbit,Skin Of Xenopus Laevis,α-Helix,Low hemolytic,CCCCSCCSCCCTTTTTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C)[C@@H](C)CC
6392,26952034,2016,ASKAGAIAGKIAKVALKAL,ASKAGAIAGKIAKVALKAL,XLAsp-P3,Free,Free,Linear,L,None,19,"Antibacterial, Anticancer",0 % Hemolysis at 32 μg/ml,Rabbit,Skin Of Xenopus Laevis,α-Helix,Low hemolytic,CCCCSCCSCCCTTTTTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C)[C@@H](C)CC
6393,26952034,2016,ASKAGAIAGKIAKVALKAL,ASKAGAIAGKIAKVALKAL,XLAsp-P4,Free,Free,Linear,L,None,19,"Antibacterial, Anticancer",6.4 % Hemolysis at 64 μg/ml,Rabbit,Skin Of Xenopus Laevis,α-Helix,Low hemolytic,CCCCSCCSCCCTTTTTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C)[C@@H](C)CC
6394,26952034,2016,ASKAGAIAGKIAKVALKAL,ASKAGAIAGKIAKVALKAL,XLAsp-P5,Free,Free,Linear,L,None,19,"Antibacterial, Anticancer",<20 % Hemolysis at 128 μg/ml,Rabbit,Skin Of Xenopus Laevis,α-Helix,Low hemolytic,CCCCSCCSCCCTTTTTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C)[C@@H](C)CC
6583,27809507,2016,PSPCGESCVFIPCISALIGCSCKNKVCYR,PSPCGESCVFIPCISALIGCSCKNKVCYR,parigidin-br3,Free,Free,Linear,L,None,29,"cytotoxic, Anticancer",~13-20 % Hemolysis at 21-42 µM,Human,Plant Palicourea Rigida,α-Helix/β-Sheet,NA,CBTTBCCTTHHHHHHIIIIISCCCCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C
6600,26949161,2016,AEAEARARAEAEARAR,AEAEARARAEAEARAR{nt:Acet}{ct:Amid},EAR16-II,Amidation,Acetylation,Linear,L,None,16,Anticancer,<5 % Hemolysis at 1.25-125 μg/ml,Rabbit,Complementary Peptide Eak16-Ii,α-Helix; β-Strand,Non-hemolytic,CCSSSCCCCCCSSSCC,C[C@H](N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
6601,26949161,2016,AEAEARAR,AEAEARAR{nt:Acet}{ct:Amid},EAR8-II,Amidation,Acetylation,Linear,L,None,8,Anticancer,<5 % Hemolysis at 1.25-125 μg/ml,Rabbit,Complementary Peptide Eak16-Ii,α-Helix; Random coil,Non-hemolytic,CCTTTSCC,C[C@H](N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
6602,26949161,2016,AAEEAARR,AAEEAARR{nt:Acet}{ct:Amid},EAR8-IIa,Amidation,Acetylation,Linear,L,None,8,Anticancer,<5 % Hemolysis at 1.25-125 μg/ml,Rabbit,Complementary Peptide Eak16-Ii,α-Helix; Random coil,Non-hemolytic,CCCSTTCC,C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
6603,26949161,2016,LLEELLRR,LLEELLRR{nt:Acet}{ct:Amid},ELR8-IIa,Amidation,Acetylation,Linear,L,None,8,Anticancer,<5 % Hemolysis at 1.25-125 μg/ml,Rabbit,Complementary Peptide Eak16-Ii,α-Helix; Random coil,Non-hemolytic,CCHHHHTC,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
7017,28165293,2017,FKCRRWQWRMKKLGAPSITCVRRAF,FKCRRWQWRMKKLGAPSITCVRRAF{cyc:N-C},LFcinB,Free,Free,Cyclic,L,None,25,Anticancer,<2 % Hemolysis at 10 µM,Human,Bovine Lf (Blf),β-Hairpin,NA,CCSCCSSTTTTTSSCCSSCCCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)[C@@H](C)O
7018,28165293,2017,FK*RRWQWRMKKLGAPSIT*VRRAF,FK{nnr:*}RRWQWRMKKLGAPSIT{nnr:*}VRRAF,LFcinB-CLICK,Free,Free,Linear,L,* = triazole linkage,23,Anticancer,<2 % Hemolysis at 10 µM,Human,Lf-Derived,β-Hairpin,NA,NA,NA
7019,28165293,2017,RRWQWR,RRWQWR{nt:Acet}{ct:Amid},LFcinB1,Amidation,Acetylation,Linear,L,None,6,Anticancer,<2 % Hemolysis at 10 µM,Human,Lf-Derived,β-Hairpin,NA,CCCCCC,N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)O
7020,28165293,2017,GRRRRSVQWCA,GRRRRSVQWCA,hLF11,Free,Free,Linear,L,None,11,Anticancer,<2 % Hemolysis at 10 µM,Human,Human-Derived,β-Hairpin,NA,CCCCCCCSSCC,CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)O
7021,28165293,2017,GRRRRSVQWSA,GRRRRSVQWSA,hLF11C10S,Free,Free,Linear,L,None,11,Anticancer,<2 % Hemolysis at 10 µM,Human,Human-Derived,β-Hairpin,NA,CCCCCCCCCCC,CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)O
7022,28165293,2017,GRRRRSVQWCA,GRRRRSVQWCA{cyc:N-C},Cyclo-hLF11,Free,Free,Cyclic,L,None,11,Anticancer,<2 % Hemolysis at 10 µM,Human,Human-Derived,β-Hairpin,NA,CCCCCCCSSCC,CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)O
7023,28165293,2017,GRRRRSVQWCA,GRRRRSVQWCA{cyc:N-C},Cyclo-hLF11C10S,Free,Free,Cyclic,L,None,11,Anticancer,<2 % Hemolysis at 10 µM,Human,Human-Derived,β-Hairpin,NA,CCCCCCCSSCC,CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)O
7024,28165293,2017,GRRRRSVQWCAGRRRRSVQWCA,GRRRRSVQWCAGRRRRSVQWCA,Dimer hLF11,Free,Free,Linear,L,None,22,Anticancer,<2 % Hemolysis at 10 µM,Human,Human-Derived,β-Hairpin,NA,CCTTSCCCSCSSCCSSCSSSCC,CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)O
7025,28165293,2017,APRKNVRWCT,APRKNVRWCT,bLF10,Free,Free,Linear,L,None,10,Anticancer,<2 % Hemolysis at 10 µM,Human,Bovine Derived,β-Hairpin,NA,CCCCCCSSCC,CC(C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)O)[C@@H](C)O
7026,28165293,2017,APRKNVRWST,APRKNVRWST,bLF10C9S,Free,Free,Linear,L,None,10,Anticancer,<2 % Hemolysis at 10 µM,Human,Bovine Derived,β-Hairpin,NA,CCCCCCCCCC,CC(C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)O)[C@@H](C)O
7027,28165293,2017,APRKNVRWCT,APRKNVRWCT{cyc:N-C},Cyclo-bLF10,Free,Free,Cyclic,L,None,10,Anticancer,<2 % Hemolysis at 10 µM,Human,Bovine Derived,β-Hairpin,NA,CCCCCCSSCC,CC(C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)O)[C@@H](C)O
7028,28165293,2017,APRKNVRWCTAPRKNVRWCT,APRKNVRWCTAPRKNVRWCT,Dimer bLF10,Free,Free,Linear,L,None,20,Anticancer,<2 % Hemolysis at 10 µM,Human,Bovine Derived,β-Hairpin,NA,CCSCCCCTTSCCTTCCSSCC,CC(C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)O)[C@@H](C)O
7029,28165293,2017,APRKNVRWCTISQPEW,APRKNVRWCTISQPEW,bLF16,Free,Free,Linear,L,None,16,Anticancer,<2 % Hemolysis at 10 µM,Human,Bovine Derived,β-Hairpin,NA,CCCSSSCCSCCCTTCC,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O
7030,28165293,2017,GRRRRSVQWCAPRRWQWR,GRRRRSVQWCAPRRWQWR{ct:Amid},hLF11-P-LFcinB1,Amidation,Free,Linear,L,None,18,Anticancer,<2 % Hemolysis at 10 µM,Human,Human-Derived,β-Hairpin,NA,CCCSSCCCCCCCBTTBBC,CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
7031,28165293,2017,GRRRRSVQWCAGGRRWQWR,GRRRRSVQWCAGGRRWQWR{ct:Amid},hLF11-GG-LFcinB1,Amidation,Free,Linear,L,None,19,Anticancer,<2 % Hemolysis at 10 µM,Human,Human-Derived,β-Hairpin,NA,CCCSCCSSCSSCSSSSSCC,CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
7032,28165293,2017,GIGAVLKVLTTGLPALISWIKRKRQQ,GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid},Melittin,Amidation,Free,Linear,L,None,26,Anticancer,90 % Hemolysis at 10 µM,Human,Bee Venom,Helical,NA,CCHHHHHHHTTSCHHHHTTTTTTSCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C
7208,28422156,2017,ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEWGCPCQL,ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEWGCPCQL,Laterosporulin10 (LS10),Free,Free,Linear,L,None,53,Anticancer,0 % Hemolysis at 1-40 µM,Rabbit,Brevibacillus Sp. Strain Skdu10,Randomic structures in 5% SDS and 100% TFE,Non-hemolytic,CGGGTSCCTHHHHTSSCSSCSHHHHHHHHHTCSSCSSSCCCCCSSSSSSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)O)C(C)C)C(C)C)C(C)C)C(C)C)[C@@H](C)CC
7464,27937055,2017,GHHNGR,GHHNGR,oleylpeptide,Free,Free,Linear,L,None,6,Anticancer,1.3 ± 0.04 % Hemolysis at 2 mM,Human,Resin,β-Turns and Bent,Non-hemolytic,CCCC,N=C(N)NCCC[C@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CN)C(=O)O
8288,37867694,2023,RWQWRWQWR,RWQWRWQWR,[Pal],Free,Free,Linear,L,None,9,Anticancer,13.2 % Hemolysis at 200 μg/ml,Human,Bovine Lactoferricin,α-Helical,NA,NA,N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)O
8289,37867694,2023,AhxRWQWRWQWR,{nnr:Ahx}RWQWRWQWR,Ahx-[Pal],Free,Free,Linear,L,Ahx = amino hexanoic acid,9,Anticancer,7.7 % Hemolysis at 200 μg/ml,Human,Synthetic,α-Helical,NA,NA,NA
8290,37867694,2023,RWQWRWQWOrn,RWQWRWQW{nnr:O},9[Orn] [Pal],Free,Free,Linear,L,O = L-Ornithine,8,Anticancer,6.6 % Hemolysis at 200 μg/ml,Human,Synthetic,α-Helical,NA,NA,NA
8618,37734650,2024,KLKSKLMVVCNKIGLLKSLCRKFVKSH,KLKSKLMVVCNKIGLLKSLCRKFVKSH,NKL-WT,Free,Free,Linear,L,None,27,Antibacterial and Anticancer,16.3 % Hemolysis at 40 µM,Rabbit,Antarctic Teleost Trematomus Bernacchii,α-Helical,NA,CCCCCSGGGSTHHHHHHHHSSSCCCCCSSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O)C(C)C
8619,37734650,2024,KLKSKLMVVCNKIGLLKSLCRKFVKSH,KLKSKLMVVCNKIGLLKSLCRKFVKSH,NKL-WT,Free,Free,Linear,L,None,27,Antibacterial and Anticancer,40.5 % Hemolysis at 80 µM,Rabbit,Antarctic Teleost Trematomus Bernacchii,α-Helical,NA,CCCCCCGGGSTHHHHHHHHSSSCCSSSCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O)C(C)C
8620,37734650,2024,KLKSKLMVVANKIGLLKSLARKFVKSH,KLKSKLMVVANKIGLLKSLARKFVKSH,NKL-MUT,Free,Free,Linear,L,None,27,Antibacterial and Anticancer,0.9 % Hemolysis at 5 µM,Rabbit,Antarctic Teleost Trematomus Bernacchii,α-Helical,NA,CCCCCCGGGSTHHHHHHHHSSSCCSSSCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O)C(C)C
8621,37734650,2024,KLKSKLMVVANKIGLLKSLARKFVKSH,KLKSKLMVVANKIGLLKSLARKFVKSH,NKL-MUT,Free,Free,Linear,L,None,27,Antibacterial and Anticancer,2.6 % Hemolysis at 80 µM,Rabbit,Antarctic Teleost Trematomus Bernacchii,α-Helical,NA,CCSSSCCHHHHHHHHHHHHHHHSSSCCSTTGGGTHHHHHHHHHHHGGGSHHHHHHHHHHHTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O)C(C)C
8647,37880286,2024,GIGAVLKVLTTGLPALISWIKRKRQQ,GIGAVLKVLTTGLPALISWIKRKRQQ,Mel,Free,Free,Linear,L,None,26,Anticancer,<40 % Hemolysis at 256 μg/ml,Human,Bee Venom,α-Helical,NA,CHHHHHHHHHHHC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C
8648,37880286,2024,CGIGAVLKVLTTGLPALISWIKRKRQQ,CGIGAVLKVLTTGLPALISWIKRKRQQ,C-Mel,Free,Free,Linear,L,None,27,Anticancer,30 % Hemolysis at 256 μg/ml,Human,Synthetic,α-Helical,NA,CHHHHHHHHHHHC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CS)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C
8649,37880286,2024,GIGAVLKVLTTGLPALISWIKRKRQQC,GIGAVLKVLTTGLPALISWIKRKRQQC,Mel-C,Free,Free,Linear,L,None,27,Anticancer,<40 % Hemolysis at 256 μg/ml,Human,Synthetic,α-Helical,NA,CCHHHHHHHHHHHHHHHHHHHHHHHHHHTTTTTCCCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C
8680,29196622,2017,NLys-Nspe-Nspe-NLys-Nspe-Nspe-NLys-Nspe-Nspe-NLys-Nspe-Nspe,{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid},peptoid 1,Amidation,H,Linear,L,"Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine",12,"Anticancer, Antimicrobial",10 % Hemolysis at 14 µM,Human,Synthetic,NA,NA,NA,NA
8694,29196622,2017,NLys-Nspe-Nspe-NLys-Nspe-Nspe-NLys-Nspe-Nspe-NLys-Nspe-Nspe,{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid},peptoid 1,Amidation,H,Linear,L,"Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine",12,"Anticancer, Antimicrobial",50 % Hemolysis at 62 µM,Human,Synthetic,NA,NA,NA,NA
8869,29280948,2017,KWKSFLKTFKSAKKTVLHTALKAISS,KWKSFLKTFKSAKKTVLHTALKAISS{nt:Acet}{ct:Amid},V13K,Amidation,Acetylation,Linear,L,None,26,"Antimicrobial, Anticancer",<20 % Hemolysis at 250 µM,Human,Magainin (African Clawed Frog),α-Helical,Low hemolytic,CCHHHHHHHHHHHHHHHHHHHHSSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O
9128,29643444,2018,TVLRGCWTFSFPPKPCI,TVLRGCWTFSFPPKPCI{ct:Amid},HECI,Amidation,Free,Linear,L,None,17,Anticancer,<15 % Hemolysis at 128 µM,Horse,Frogs (Hylarana Erythraea Chymotrypsin Inhibitor),NA,NA,CCSSSSSSSSSSSSSCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)O
9136,29670004,2018,FFSLIPKLVKGLISAFK,FFSLIPKLVKGLISAFK{ct:Amid},StigA6,Amidation,Free,Linear,L,None,17,"Antiparasitic, Antimicrobial, Anticancer",30 % Hemolysis at 75 µM,Human,Analogs To Stigmurin,Random coil,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)O
9137,29670004,2018,FFKLIPKLVKGLISAFK,FFKLIPKLVKGLISAFK{ct:Amid},StigA16,Amidation,Free,Linear,L,None,17,"Antiparasitic, Antimicrobial, Anticancer",30 % Hemolysis at 75 µM,Human,Analogs To Stigmurin,Random coil,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)O
9148,29549839,2018,SKVWRHWRRFWHRAHRKL,{conj:CH3(CH2)14CO}SKVWRHWRRFWHRAHRKL,PA-C1b,Free,CH3(CH2)14CO,Linear,L,palmitic acid (PA) conjugation of aliphatic acid was designed lipo-chensinin-1b,14,Anticancer and Anti-inflammation,0 % Hemolysis at >500 µM,Human,Designed Lipo-Chensinin-1B,"Random coil at aq, β-Strand at TFE solution",Non-hemolytic,NA,NA
9151,29904274,2018,RKKRRQRRRLNLKALLAVAKKIL,RKKRRQRRRLNLKALLAVAKKIL{ct:Amid},tMP-C,Amidation,Free,Linear,L,None,23,Anticancer,50 % Hemolysis at 77.94 µM,Horse,Modifcation In Mp-N-Terminal Extension Via Tat-Linked,"Random-coil at aq, α-Helical at membrane mimic solution",NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(=N)N)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O
9399,29770868,2018,GIGAVLKVLTTGLPALISWIKRKRQQ,GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid},melittin monomer,Amidation,Free,Linear,L,None,26,"Antibacterial, Anticancer",100 % Hemolysis at 10 µM,mouse,Bee Venom,α-Helix,NA,CCHHHHHHHTTSCHHHHTTTTTTSCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C
9402,29842923,2018,SILPTIVSFLSKVF,SILPTIVSFLSKVF,Temporin-1Ga,Free,Free,Linear,L,None,14,"Antibacterial, Antifungal, Anticancer",50 % Hemolysis at 12.5 µM,Human,Frog Rana Grylio,NA,NA,CTHHHHTTTSTHHHHHHHHTTCC,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C
9403,29842923,2018,FLPFLKSILGKIL,FLPFLKSILGKIL,Temporin-1OLa,Free,Free,Linear,L,None,13,"Antibacterial, Antifungal, Anticancer",50 % Hemolysis at 50 µM,Human,Frog Rana Okaloosae,α-Helical,NA,CGGGTHHHHHHHHHHHTGGGTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O
9409,29931753,2018,GIGAVLKVLTTGLPALISWIKRKRQQ,GIGAVLKVLTTGLPALISWIKRKRQQ{nt:-NH2/Ce6},MEL/Ce6,Free,#DIV/0!,Linear,L,Ce6 = porphyrin derivatives chlorin e6,26,Anticancer,>30 % Hemolysis at 40 µM,mouse,Modified Melittin,NA,NA,CCCCCCCC,NA
9410,29931753,2018,GIGAVLKVLTTGLPALISWIKRKRQQ,GIGAVLKVLTTGLPALISWIKRKRQQ{nt:NH2/Ce6@HA},MEL/Ce6@HA,Free,NH2/Ce6@HA,Linear,L,"Ce6 = porphyrin derivatives chlorin e6, HA = hyaluronic acid",26,Anticancer,>10 % Hemolysis at 40 µM,mouse,Modified Melittin,NA,NA,CCCCCCCTTSSCC,NA
9413,30087268,2018,ALWKDILKNLLKAALNEINQIVQ,ALWKDILKNLLKAALNEINQIVQ{ct:Amid},"L10, 11-DPS3",Amidation,Free,Linear,L,None,23,"Antimicrobial, Anticancer",50 % Hemolysis at 3.44 µM,Horse,Analogs Of Dermaseptin-Ps3,"aqueous = Random coils, membrane-mimicking solution = α-Helical",NA,CCCCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)O)C(C)C)[C@@H](C)CC)[C@@H](C)CC
9528,30240951,2018,VNWKKILGKIIKVVK,VNWKKILGKIIKVVK{ct:Amid},Lasioglossin-III,Amidation,Free,Linear,L,None,15,"Antimicrobial, Anticancer",>35 % Hemolysis at 10 µM,Human,Derived From Bee Venom,α-Helix,NA,CCCSTHHHHGGGHHHHSSSCSSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C)[C@@H](C)CC)[C@@H](C)CC
9531,30240951,2018,VNWKKILGKIIKVVK,VNWKKILGKIIKVVK{ct:Amid},Lasioglossin-III,Amidation,Free,Linear,L,None,15,"Antimicrobial, Anticancer",100 % Hemolysis at 100 µM,Human,Derived From Bee Venom,α-Helix,NA,CCCSTHHHHGGGHHHHSSSCSSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C)[C@@H](C)CC)[C@@H](C)CC
9635,30387611,2018,GLPICGETCVFGKCNTPGCSCRRPICYKN,GLPICGETCVFGKCNTPGCSCRRPICYKN{cyc:N-C},Rivi1,Free,Free,Cyclic,L,None,29,Anticancer,50 % Hemolysis at ≫10 µM,Human,Plant Rinorea Virgata,Loop,NA,CHHHHHHHHHTTTTSSSCCCC,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)O
9636,30387611,2018,GSYLCGETCVQGKCYTPGCTCSWPICKKN,GSYLCGETCVQGKCYTPGCTCSWPICKKN{cyc:N-C},Rivi2,Free,Free,Cyclic,L,None,29,Anticancer,50 % Hemolysis at ≫10 µM,Human,Plant Rinorea Virgata,Loop,NA,CHHHHHHHHHTTTTSSSCCCC,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)CN)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)O
9637,30387611,2018,GLPICGETCLLGKCYTPGCSCRRPVCYKN,GLPICGETCLLGKCYTPGCSCRRPVCYKN{cyc:N-C},Rivi3,Free,Free,Cyclic,L,None,29,Anticancer,50 % Hemolysis at ≫10 µM,Human,Plant Rinorea Virgata,Loop,NA,CHHHHHHHHHTTTTSSSCCCC,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C)[C@@H](C)O)[C@@H](C)O
9675,30622471,2018,GRFKRFRKKLKRLWHKVGPFVGPILHY,GRFKRFRKKLKRLWHKVGPFVGPILHY,ChMAP-28,Free,Free,Linear,L,None,27,Anticancer,<10 % Hemolysis at 10 µM,Human,Capra Hircus Goat Leukocytes,α-Helix,NA,CCHHHHHHHIIIIITTC,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(C)C)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O
9676,30622471,2018,GRFKRFRKKLKRLWHKVGPFVGPILHY,GRFKRFRKKLKRLWHKVGPFVGPILHY,ChMAP-28,Free,Free,Linear,L,None,27,Anticancer,50 % Hemolysis at ~100 µM,Human,Capra Hircus Goat Leukocytes,α-Helix,NA,CCSSSHHHHIIIIITTC,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(C)C)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O
9747,30701481,2019,GLPLLISWIKRKRQQGSKKPVPIIYCNRRTGKCQRM,GLPLLISWIKRKRQQGSKKPVPIIYCNRRTGKCQRM,Hybrid Peptide,Free,Free,Linear,L,None,36,"Antibacterial, Anticancer",0 % Hemolysis at 45 μmol/L,Sheep,Mutant Fragments Of Melittin And Thanatin,x,Non-hemolytic,CCCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(C)C
9769,30612735,2019,FLSLIPHIASGIASLVKNF,FLSLIPHIASGIASLVKNF{ct:Amid},Phylloseptin-PBa1,Amidation,Free,Linear,L,None,19,"Antimicrobial, Anticancer",50 % Hemolysis at 18.6 µM,Horse,Leaf Forg (Phyllomedusa Burmeisteri),α-Helix,NA,NA,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C
9770,30612735,2019,FLSLLPHIASGIASLVSKF,FLSLLPHIASGIASLVSKF{ct:Amid},Phylloseptin-PBa2,Amidation,Free,Linear,L,None,19,"Antimicrobial, Anticancer",50 % Hemolysis at 15.82 µM,Horse,Leaf Forg (Phyllomedusa Burmeisteri),α-Helix,NA,NA,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C
9771,30612735,2019,FLSLIPHIVSGVAALANHL,FLSLIPHIVSGVAALANHL{ct:Amid},Phylloseptin-PBa3,Amidation,Free,Linear,L,None,19,"Antimicrobial, Anticancer",50 % Hemolysis at 52.98 µM,Horse,Leaf Forg (Phyllomedusa Burmeisteri),α-Helix,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C)C(C)C
9815,30449002,2019,IWLTALKFLGKNLGKLAKQQLAKL,IWLTALKFLGKNLGKLAKQQLAKL{ct:Amid},LyeTxI-b,Amidation,Free,Linear,L,None,24,"Anticancer, Antitumor",~35 % Hemolysis at 100 µM,Human,Spider Venom Lycosa Erythrognatha,α-Helix,Low hemolytic,NA,CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)O
9817,30481557,2019,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid},PACAP,Amidation,Free,Linear,L,None,38,"Anticancer, Antimicrobial",0 % Hemolysis at 18.75 µM,Fish,Catfish Clarias Gariepinus,α-Helix,Non-hemolytic,NA,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C)[C@@H](C)O
9818,30481557,2019,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid},PACAP,Amidation,Free,Linear,L,None,38,"Anticancer, Antimicrobial",<20 % Hemolysis at 150 µM,Fish,Catfish Clarias Gariepinus,α-Helix,NA,NA,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C)[C@@H](C)O
9819,30481557,2019,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid},PACAP,Amidation,Free,Linear,L,None,38,"Anticancer, Antimicrobial",39 % Hemolysis at 300 µM,Fish,Catfish Clarias Gariepinus,α-Helix,NA,NA,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C)[C@@H](C)O
9820,30481557,2019,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid},PACAP,Amidation,Free,Linear,L,None,38,"Anticancer, Antimicrobial",0 % Hemolysis at 75 µM,Human,Catfish Clarias Gariepinus,α-Helix,Non-hemolytic,NA,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C)[C@@H](C)O
9821,30481557,2019,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid},PACAP,Amidation,Free,Linear,L,None,38,"Anticancer, Antimicrobial",<3 % Hemolysis at 150 µM,Human,Catfish Clarias Gariepinus,α-Helix,NA,NA,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C)[C@@H](C)O
9822,30481557,2019,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid},PACAP,Amidation,Free,Linear,L,None,38,"Anticancer, Antimicrobial",6 % Hemolysis at 300 µM,Human,Catfish Clarias Gariepinus,α-Helix,NA,NA,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C)[C@@H](C)O
10466,31375699,2019,KIFKKFKTIIKKVWRIFGRF,KIFKKFKTIIKKVWRIFGRF,AmphiArc2,Free,Free,Linear,L,None,20,Anticancer,50 % Hemolysis at >15 µM,Human,Synthetic Peptide,"water = unstructured, hydrophobic environment (in 50% v/v water:2,2-trifuoroethanol, TFE) = α-Helix",NA,CCCTHHHHHHHTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
10467,31426323,2019,ALWKTLLKHVGKAAGKAALNAVTDMVNQ,ALWKTLLKHVGKAAGKAALNAVTDMVNQ{ct:Amid},Der-PS4,Amidation,Free,Linear,L,None,28,"Antimicrobial, Antibiofilm, Antiproliferative, Anticancer",50 % Hemolysis at 128 µM,Horse,"Waxy Monkey Tree Frog, Phyllomedusa Sauvagii","mimetic environment(DOPE, DOPC and DOPG, TFE) = α-Helix",NA,CHHHHGGGGGTTC,CSCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)[C@@H](C)O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O)C(C)C
10588,31252047,2019,SRSSRAGLQFPVGRIHRLLRK,SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid},Fi-His1-21,Amidation,Acetylation,Linear,L,None,21,"Antimicrobial, Anticancer",18 % Hemolysis at 400 µM,Human,"Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus",α-Helix,Low hemolytic,CGGGGGHHHHTHHHHTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O
10589,31252047,2019,SRSSRAGLQFPVGRIHRLLRK,SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid},Fi-His1-21,Amidation,Acetylation,Linear,L,None,21,"Antimicrobial, Anticancer",5 % Hemolysis at 200 µM,Human,"Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus",α-Helix,Low hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O
10590,31252047,2019,SRSSRAGLQFPVGRIHRLLRK,SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid},Fi-His1-21,Amidation,Acetylation,Linear,L,None,21,"Antimicrobial, Anticancer",0 % Hemolysis at 100 µM,Human,"Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus",α-Helix,Non-hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O
10591,31252047,2019,SRSSRAGLQFPVGRIHRLLRK,SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid},Fi-His1-21,Amidation,Acetylation,Linear,L,None,21,"Antimicrobial, Anticancer",0 % Hemolysis at 50 µM,Human,"Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus",α-Helix,Non-hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O
10592,31252047,2019,SRSSRAGLQFPVGRIHRLLRK,SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid},Fi-His1-21,Amidation,Acetylation,Linear,L,None,21,"Antimicrobial, Anticancer",0 % Hemolysis at 25 µM,Human,"Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus",α-Helix,Non-hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O
10593,31252047,2019,SRSSRAGLQFPVGRIHRLLRK,SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid},Fi-His1-21,Amidation,Acetylation,Linear,L,None,21,"Antimicrobial, Anticancer",0 % Hemolysis at 12.5 µM,Human,"Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus",α-Helix,Non-hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O
10594,31252047,2019,SRSSRAGLQFPVGRIHRLLRK,SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid},Fi-His1-21,Amidation,Acetylation,Linear,L,None,21,"Antimicrobial, Anticancer",0 % Hemolysis at 6.25 µM,Human,"Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus",α-Helix,Non-hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O
10595,31252047,2019,SRSSRAGLQFPVGRIHRLLRK,SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid},Fi-His1-21,Amidation,Acetylation,Linear,L,None,21,"Antimicrobial, Anticancer",0 % Hemolysis at 3.125 µM,Human,"Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus",α-Helix,Non-hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O
10641,31635388,2019,GLWSKIKDAAKTAGKAALGFVNEMV,GLWSKIKDAAKTAGKAALGFVNEMV,DPT9,Free,Free,Linear,L,None,25,"Antimicrobial, Antibiofilm, Anticancer",50 % Hemolysis at 210 µM,Horse,Derived From Frog Phyllomedusa Tarsius Dpt9,NA,NA,CGGGHHHHTTSCSTTTTTGGGGSCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)O)C(C)C)C(C)C)[C@@H](C)O
10642,31635388,2019,GLWSKIKKAAKTAGKAALGFVNKMV,GLWSKIKKAAKTAGKAALGFVNKMV,"K8, 23-DPT9",Free,Free,Linear,L,None,25,"Antimicrobial, Antibiofilm, Anticancer",50 % Hemolysis at 107 µM,Horse,Analogue And Modified Dtp9,NA,Low hemolytic,CCCSSSSTTTCSCCTTTCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)O)C(C)C)C(C)C)[C@@H](C)O
10945,31927997,2020,KLLKLLKKLLKLLK,KLLKLLKKLLKLLK,KL1,Free,Free,Linear,L,None,14,Anticancer,10 % Hemolysis at 0.52 µM,Human,Synthetic Peptide,"PBS buffer = α-Helical, deionized water and 0.9% NaCl = Random coil",NA,CGGGTTCTTTTC,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
10946,31927997,2020,KELKLLKKLLKLLK,KELKLLKKLLKLLK,L2E,Free,Free,Linear,L,None,14,Anticancer,10 % Hemolysis at 61.7 µM,Human,Kl1 Analogues.,"Random coil, 10%TFE = single Helix",NA,CCGGGGGHHHHHHTTSGGGGGGGGTHHHHHCC,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
10947,31927997,2020,KQLKLLKKLLKLLK,KQLKLLKKLLKLLK,L2Q,Free,Free,Linear,L,None,14,Anticancer,10 % Hemolysis at 35.5 µM,Human,Kl1 Analogues.,NA,NA,CCGGGGHHHHHHHHHHTTGGGTHHHHTTTCCC,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
10948,31927997,2020,KKLKLLKKLLKLLK,KKLKLLKKLLKLLK,L2K,Free,Free,Linear,L,None,14,Anticancer,10 % Hemolysis at 19.5 µM,Human,Kl1 Analogues.,NA,NA,CCCCCCCTTSSSTTSSSCCSTTCC,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
11035,32443921,2020,FLGAILKIGHALAKTVLPMVTNAFKPKQ,FLGAILKIGHALAKTVLPMVTNAFKPKQ,Figainin 2,Free,Free,Linear,L,None,28,"Antibacterial, Anticancer, Anti-Epimastigote, Antiviral, Antitrypanosomal, exhibits immunomodulatory effects in human neutrophils",50 % Hemolysis at 48.9 µM,Human,"Skin Chaco Tree Frog, Boana Raniceps","α-Helix, Milli-Q water and 10% (v/v) TFE = Random coil, 30% and 50% (v/v) TFE = α-Helix",NA,CCSCCSCSSCCCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)O)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)CC
11036,32443921,2020,FLGAILKIGHALAKTVLPMVTNAFKPKQ,FLGAILKIGHALAKTVLPMVTNAFKPKQ,Figainin 2,Free,Free,Linear,L,None,28,"Antibacterial, Anticancer, Anti-Epimastigote, Antiviral, Antitrypanosomal, exhibits immunomodulatory effects in human neutrophils",23 % Hemolysis at 32 µM,Human,"Skin Chaco Tree Frog, Boana Raniceps","α-Helix, Milli-Q water and 10% (v/v) TFE = Random coil, 30% and 50% (v/v) TFE = α-Helix",NA,CCTTSSSSCCCSSCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)O)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)CC
11037,32443921,2020,FLGAILKIGHALAKTVLPMVTNAFKPKQ,FLGAILKIGHALAKTVLPMVTNAFKPKQ,Figainin 2,Free,Free,Linear,L,None,28,"Antibacterial, Anticancer, Anti-Epimastigote, Antiviral, Antitrypanosomal, exhibits immunomodulatory effects in human neutrophils",9 % Hemolysis at 16 µM,Human,"Skin Chaco Tree Frog, Boana Raniceps","α-Helix, Milli-Q water and 10% (v/v) TFE = Random coil, 30% and 50% (v/v) TFE = α-Helix",NA,CCTTSCCCGGGGSTTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)O)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)CC
11049,32347293,2020,FLGALFKVASKLVPAAICSISKKC,FLGALFKVASKLVPAAICSISKKC,Brevinin-1GHd,Free,Free,Linear,L,None,24,"Antimicrobial, Anticancer, Antibiotic, Anti-biofilm",13 % Hemolysis at 32 µM,Horse,"Frog Skin, Hylarana Guenther","aqueous(10 mM NH4AC buffer) = Random coil, membrane-mimetic environment (50% TFE in 10 mM NH4AC)membrane-mimetic environment (50% TFE in 10 mM NH4AC) = α-Helix",NA,CTHHHHHHHHHHHHHHHHHTTCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)CC
11150,32567085,2020,FKRIVQRIKDFLR,FKRIVQRIKDFLR{ct:Amid},1,Amidation,NA,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 0 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,Non-hemolytic,CTTHHHHHHHHHC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11151,32567085,2020,LKRIVQRIKDFLR,LKRIVQRIKDFLR{ct:Amid},2,Amidation,NA,Linear,L,None,13,"Antibacterial, Anticancer",50 % Hemolysis at 0 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,Non-hemolytic,CTTHHHHHHHHHC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(C)C)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11152,32567085,2020,AKRIVQRIKDFLR,AKRIVQRIKDFLR{ct:Amid},3,Amidation,NA,Linear,L,None,13,"Antibacterial, Anticancer",50 % Hemolysis at 0 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,Non-hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)N)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11153,32567085,2020,FκRIVQRILDFLR,F{nnr:κ}RIVQRILDFLR{nt:Acet}{ct:Amid},4,Amidation,Acetylation,Linear,L,κ = κ,13,"Antibacterial, Anticancer",50 % Hemolysis at 450 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,NA,NA,NA
11154,32567085,2020,FK(SA)RIVQRILDFLR,FK{nnr:SA}RIVQRILDFLR{nt:Acet}{ct:Amid},5,Amidation,Acetylation,Linear,L,SA = SA,14,"Antibacterial, Anticancer",50 % Hemolysis at 0 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,Non-hemolytic,NA,NA
11155,32567085,2020,FKRIVQRIRDFLR,FKRIVQRIRDFLR{ct:Amid},6,Amidation,NA,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 0 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,Non-hemolytic,CGGGGGGHHHHHC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11156,32567085,2020,FKRIVQRIRDFLR,FKRIVQRIRDFLR{nt:Acet}{ct:Amid},7,Amidation,Acetylation,Linear,L,None,13,"Antibacterial, Anticancer",50 % Hemolysis at 0 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,Non-hemolytic,CGGGGGGHHHHHC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11157,32567085,2020,FKRIVQκIKDFLR,FKRIVQ{nnr:κ}IKDFLR{ct:Amid},8,Amidation,NA,Linear,L,κ = κ,13,"Antibacterial, Anticancer",50 % Hemolysis at 0 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,Non-hemolytic,NA,NA
11158,32567085,2020,FKRIVQLIKDFLR,FKRIVQLIKDFLR{ct:Amid},9,Amidation,NA,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 114 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,NA,CTTHHHHHTTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11159,32567085,2020,FKRIVQLIKDFLR,FKRIVQLIKDFLR{nt:Acet}{ct:Amid},10,Amidation,Acetylation,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 227 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,NA,CGGGHHHHTTCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11160,32567085,2020,FKRIVQRIKDLLR,FKRIVQRIKDLLR{ct:Amid},11,Amidation,NA,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 0 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,Non-hemolytic,CGGGHHHHTTCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11161,32567085,2020,FKRIVQRIKDLLR,FKRIVQRIKDLLR{nt:Acet}{ct:Amid},12,Amidation,Acetylation,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 0 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,Non-hemolytic,CGGGGGGHHHHTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11162,32567085,2020,FKRIVQIIKKFLR,FKRIVQIIKKFLR{ct:Amid},13,Amidation,NA,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 361 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,NA,CGGGGGGHHHHTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)C(C)C
11163,32567085,2020,FKRIVQIIKKFLR,FKRIVQIIKKFLR{nt:Acet}{ct:Amid},14,Amidation,Acetylation,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 292 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)C(C)C
11164,32567085,2020,FKRIVQLLKKLLR,FKRIVQLLKKLLR{ct:Amid},15,Amidation,NA,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 411 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C
11165,32567085,2020,FKRIVQLLKKLLR,FKRIVQLLKKLLR{nt:Acet}{ct:Amid},16,Amidation,Acetylation,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 185 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C
11166,32567085,2020,FKRILQRIKDFLR,FKRILQRIKDFLR{ct:Amid},17,Amidation,NA,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 0 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,Non-hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11167,32567085,2020,FKRILQRIKDFLR,FKRILQRIKDFLR{nt:Acet}{ct:Amid},18,Amidation,Acetylation,Linear,L,None,13,"Antibacterial,Antifungal, Anticancer",50 % Hemolysis at 0 μg/ml,Human,Derivedm From Cathelicidin Ll-37,α-Helix,Non-hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11238,32126228,2020,VRRFPWWWPFLRR,VRRFPWWWPFLRR,Tritrpticin,Free,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Trp-Rich Porcine Cathelicidin Peptide,NA,NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11239,32126228,2020,VRRFPWWWPFLRR,VRRFPWWWPFLRR{ct:Amid},Tritrp-Arg,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at 62.2 µM,Human,Modification Tritrpticin,NA,NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11240,32126228,2020,V(Agb)(Agb)FPWWWPFL(Agb)(Agb),V{nnr:Agb}{nnr:Agb}FPWWWPFL{nnr:Agb}{nnr:Agb}{ct:Amid},Tritrp-Agb,Amidation,Free,Linear,L,Agb = (S)-2-amino-4 guanidinobutyric acid,13,Anticancer,50 % Hemolysis at 34.6 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11241,32126228,2020,V(hArg)(hArg)FPWWWPFL(hArg)(hArg),V{nnr:hArg}{nnr:hArg}FPWWWPFL{nnr:hArg}{nnr:hArg}{ct:Amid},Tritrp-hArg,Amidation,Free,Linear,L,hArg = homo-arginine Arg Derivative,13,Anticancer,50 % Hemolysis at 41.3 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11242,32126228,2020,VKKFPWWWPFLKK,VKKFPWWWPFLKK{ct:Amid},Tritrp-Lys,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCCSCTHHHHHCC,NA
11243,32126228,2020,V(Dap)(Dap)FPWWWPFL(Dap)(Dap),V{nnr:Dap}{nnr:Dap}FPWWWPFL{nnr:Dap}{nnr:Dap}{ct:Amid},Tritrp-Dap,Amidation,Free,Linear,L,"Dap = 2,3-diaminopropionic acid Lys Derivative",13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11244,32126228,2020,V(Dab)(Dab)FPWWWPFL(Dab)(Dab),V{nnr:Dab}{nnr:Dab}FPWWWPFL{nnr:Dab}{nnr:Dab}{ct:Amid},Tritrp-Dab,Amidation,Free,Linear,L,"Dab = 2,4-diaminobutyric acid Lys Derivative",13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11245,32126228,2020,VOOFPWWWPFLOO,V{nnr:O}{nnr:O}FPWWWPFL{nnr:O}{nnr:O}{ct:Amid},Tritrp-Orn,Amidation,Free,Linear,L,O = L-Ornithine,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11246,32126228,2020,VRRFAWWWAFLRR,VRRFAWWWAFLRR{ct:Amid},Tritrp-P59A,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at 52.5 µM,Human,Modification Tritrpticin,NA,NA,CCCCCCHHHHTCC,NA
11247,32126228,2020,VKKFAWWWAFLKK,VKKFAWWWAFLKK{ct:Amid},Tritrp-P59A-Lys,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCSSSSSHHHHTC,NA
11248,32126228,2020,VRRFAWWWPFLRR,VRRFAWWWPFLRR{ct:Amid},Tritrp-P5A,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11249,32126228,2020,VKKFAWWWPFLKK,VKKFAWWWPFLKK{ct:Amid},Tritrp-P5A-Lys,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11250,32126228,2020,VRRFPWWWAFLRR,VRRFPWWWAFLRR{ct:Amid},Tritrp-P9A,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at 29.3 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11251,32126228,2020,VKKFPWWWAFLKK,VKKFPWWWAFLKK{ct:Amid},Tritrp-P9A-Lys,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11252,32126228,2020,VRRFPFFFPFLRR,VRRFPFFFPFLRR{ct:Amid},Tritrp-W678F,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11253,32126228,2020,VRRFP(bTA)(bTA)(bTA)PFLRR,VRRFP{nnr:bTA}{nnr:bTA}{nnr:bTA}PFLRR{ct:Amid},Tritrp-W678bTA,Amidation,Free,Linear,L,bTA = β-3-benzothienyl-1-AlaTrpDerivative,13,Anticancer,50 % Hemolysis at 12.2 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11254,32126228,2020,VRRFP(hW)WWPFLRR,VRRFP{nnr:hW}WWPFLRR{ct:Amid},Tritrp-W6hW,Amidation,Free,Linear,L,hW = 5-hydroxytryptophan Trp Derivative,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11255,32126228,2020,VRRFPW(hW)WPFLRR,VRRFPW{nnr:hW}WPFLRR{ct:Amid},Tritrp-W7hW,Amidation,Free,Linear,L,hW = 5-hydroxytryptophan Trp Derivative,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11256,32126228,2020,VRRFPWW(hW)PFLRR,VRRFPWW{nnr:hW}PFLRR{ct:Amid},Tritrp-W8hW,Amidation,Free,Linear,L,hW = 5-hydroxytryptophan Trp Derivative,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11257,32126228,2020,VRRFP(hW)(hW)(hW)PFLRR,VRRFP{nnr:hW}{nnr:hW}{nnr:hW}PFLRR{ct:Amid},Tritrp-W678hW,Amidation,Free,Linear,L,hW = 5-hydroxytryptophan Trp Derivative,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,NA,NA
11258,32126228,2020,VRRFPAWWPFLRR,VRRFPAWWPFLRR{ct:Amid},Tritrp-W6A,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCCSCCCCTTTCC,NA
11259,32126228,2020,VRRFPWAWPFLRR,VRRFPWAWPFLRR{ct:Amid},Tritrp-W7A,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCCCSSSSSCTTC,NA
11260,32126228,2020,VRRFPWWAPFLRR,VRRFPWWAPFLRR{ct:Amid},Tritrp-W8A,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCSSSSCCSSCCC,NA
11261,32126228,2020,VRRFPAAWPFLRR,VRRFPAAWPFLRR{ct:Amid},Tritrp-W67A,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CTTTTCCCCCCCC,NA
11262,32126228,2020,VRRFPAWAPFLRR,VRRFPAWAPFLRR{ct:Amid},Tritrp-W68A,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCCCSSSSGGGGC,NA
11263,32126228,2020,VRRFPWAAPFLRR,VRRFPWAAPFLRR{ct:Amid},Tritrp-W78A,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCTTTCSCSSCCC,NA
11264,32126228,2020,VRRFPAAAPFLRR,VRRFPAAAPFLRR{ct:Amid},Tritrp-W678A,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCSSCSCSSSSCC,NA
11265,32126228,2020,VRRFPYWWPFLRR,VRRFPYWWPFLRR{ct:Amid},Tritrp-W6Y,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCCSCCCCCCCCC,NA
11266,32126228,2020,VRRFPWYWPFLRR,VRRFPWYWPFLRR{ct:Amid},Tritrp-W7Y,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCSSSCSSSSCCC,NA
11267,32126228,2020,VRRFPWWYPFLRR,VRRFPWWYPFLRR{ct:Amid},Tritrp-W8Y,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CBTTBCCHHHHTSCC,NA
11268,32126228,2020,VRRFPYYWPFLRR,VRRFPYYWPFLRR{ct:Amid},Tritrp-W67Y,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCSTTCCCGGGHHHHTTGGGGC,NA
11269,32126228,2020,VRRFPYWYPFLRR,VRRFPYWYPFLRR{ct:Amid},Tritrp-W68Y,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCGGGCSHHHHTTCGGGGGGGC,NA
11270,32126228,2020,VRRFPWYYPFLRR,VRRFPWYYPFLRR{ct:Amid},Tritrp-W78Y,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CCCSSCCCCCCCC,NA
11271,32126228,2020,VRRFPYYYPFLRR,VRRFPYYYPFLRR{ct:Amid},Tritrp-W678Y,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Modification Tritrpticin,NA,NA,CHHHHSSCCSSCC,NA
11272,32126228,2020,CVRRFPWWYPFLRRC,CVRRFPWWYPFLRRC{cyc:N-C}{ct:Amid},Tritrp-DiSu*,Amidation,Free,Cyclic,L,None,15,Anticancer,50 % Hemolysis at 20.9 µM,Human,Modification Tritrpticin,NA,NA,CCCCCCSCCCTTC,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](N)CS)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)O
11273,32126228,2020,GIGKWLHSAKKFGKAFVGEIMNS,GIGKWLHSAKKFGKAFVGEIMNS,MagaininF5W-Lys,Free,Free,Linear,L,None,23,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,CCSSCCSSTTSCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)O)[C@@H](C)CC)C(C)C
11274,32126228,2020,GIGRWLHSARRFGRAFVGEIMNS,GIGRWLHSARRFGRAFVGEIMNS,MagaininF5W-Arg,Free,Free,Linear,L,None,23,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,CCCCSTTCCCCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)O)[C@@H](C)CC)C(C)C
11275,32126228,2020,FPVTWRWWRWWRG,FPVTWRWWRWWRG{ct:Amid},PuroA-Arg,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,NA,CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)[C@@H](C)O
11276,32126228,2020,FPVTWKWWKWWKG,FPVTWKWWKWWKG{ct:Amid},PuroA-Lys,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,CCCBTTBCCCCSSCCCCCCCSSCCCCC,CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O)[C@@H](C)O
11277,32126228,2020,ILPWKWPWWPWRR,ILPWKWPWWPWRR{ct:Amid},Indolicidin-Arg,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,CCSSCCCCCCCCCCCSSCCCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11278,32126228,2020,ILPWKWPWWPWKK,ILPWKWPWWPWKK{ct:Amid},Indolicidin-Lys,Amidation,Free,Linear,L,None,13,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,CCCCCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
11279,32126228,2020,FRVTWRTKWWKG,FRVTWRTKWWKG{ct:Amid},PuroB3,Amidation,Free,Linear,L,None,12,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,CCSCC,CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O)[C@@H](C)O)[C@@H](C)O
11280,32126228,2020,FRVT(hW)RTK(hW)(hW)KG,FRVT{nnr:hW}RTK{nnr:hW}{nnr:hW}KG{ct:Amid},PuroB3-hW,Amidation,Free,Linear,L,hW = 5-hydroxytryptophan Trp Derivative,12,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,NA,NA
11281,32126228,2020,GALFLGFLGAAGSTMGAWSQPKKKRKV,GALFLGFLGAAGSTMGAWSQPKKKRKV{nt:Acet}{ct:CM = CysteAmidation},MPG,CM = CysteAmidation,Acetylation,Linear,L,CM = CysteAmidation,27,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,NA,NA
11282,32126228,2020,KETWWETWWTEWSQPKKKRKV,KETWWETWWTEWSQPKKKRKV{nt:Acet}{ct:CM = CysteAmidation},Pep-1,CM = CysteAmidation,Acetylation,Linear,L,CM = CysteAmidation,21,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,NA,NA
11283,32126228,2020,RRWWRF,RRWWRF{nt:Acet}{ct:Amid},Combi-1,Amidation,Acetylation,Linear,L,None,6,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,CCSSSCCCC,N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
11284,32126228,2020,FRWWHR,FRWWHR{nt:Acet}{ct:Amid},Combi-2,Amidation,Acetylation,Linear,L,None,6,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,NA,N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)O
11285,32126228,2020,RAWVAWR,RAWVAWR{ct:Amid},LysH,Amidation,Free,Linear,L,None,7,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,NA,CC(C)[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
11286,32126228,2020,TRSSRAGLQFPVGRVHRLLRK,TRSSRAGLQFPVGRVHRLLRK,Buforin-2,Free,Free,Linear,L,None,21,Anticancer,50 % Hemolysis at ≥65 µM,Human,Antimicrobial Peptides,NA,NA,NA,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C
11287,32126228,2020,GIGAVLKVLTTGLPAALISWIKRKRQQ,GIGAVLKVLTTGLPAALISWIKRKRQQ{ct:Amid},Melittin,Amidation,Free,Linear,L,None,21,Anticancer,50 % Hemolysis at ≤6.5 µM,Human,Antimicrobial Peptides,NA,NA,NA,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C
11325,32752241,2020,HHWRRYARIGFRAVRTVIGK,HHWRRYARIGFRAVRTVIGK{ct:Amid},Trichoplaxin-2 [T2],Amidation,Free,Linear,L,None,20,"Antimicrobial, Anticancer",10 % Hemolysis at 1.4 µM,Human,Phylum Placozo Trichoplax Adhaerens,Helical,NA,CHHHHTHHHHGGGTSCSSSSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C)[C@@H](C)O)C(C)C
11326,32752241,2020,RHHWRRYARIGFRAVRTVIGK,RHHWRRYARIGFRAVRTVIGK{ct:Amid},Trichoplaxin-2A [T2R1],Amidation,Free,Linear,L,None,21,"Antimicrobial, Anticancer",10 % Hemolysis at 3 µM,Human,Analog Of Trichoplaxin-2,Helical,NA,CCTTCGGGTCCTHHHHGGGC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C)[C@@H](C)O)C(C)C
11327,32752241,2020,GIKKAVGKALKGLKGLLKALGES,GIKKAVGKALKGLKGLLKALGES{ct:Amid},Adepantin-1A [A1A],Amidation,Free,Linear,L,None,23,"Antimicrobial, Anticancer",10 % Hemolysis at 25 µM,Human,Adepantin-1 Analog,Helical,NA,CCCSSCTTTCTTTSTTTTTC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)C(C)C
11328,32752241,2020,GIGKFLKKAKKFGKAFVLILKK,GIGKFLKKAKKFGKAFVLILKK{ct:Amid},Pexiganan-L18 [PEXA],Amidation,Free,Linear,L,None,22,"Antimicrobial, Anticancer",10 % Hemolysis at 1.6 µM,Human,Pexiganan Analog,Helical,NA,CGGGGGHHHHTTTTTTCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C
11329,32752241,2020,GIKKWVKGVAKGVAKDLAKKIL,GIKKWVKGVAKGVAKDLAKKIL{ct:Amid},Flexampin [FLEX],Amidation,Free,Linear,L,None,22,"Antimicrobial, Anticancer",10 % Hemolysis at 6 µM,Human,Template From Ranatuerin-2Csa,Helical,NA,CCHHHHHHHHTTTC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)C(C)C)C(C)C)C(C)C
11330,32752241,2020,GIGREIIKKIIKKIGKKIGRII,GIGREIIKKIIKKIGKKIGRII{ct:Amid},Zyk-1 [ZYK1],Amidation,Free,Linear,L,None,22,"Antimicrobial, Anticancer",10 % Hemolysis at 3 µM,Human,Zyk Strain Of Bacillus Oryziterrae Peptide,Helical,NA,CTTTTTSTHHHHGGGTCC,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(=O)O
11331,32752241,2020,KIAKVALKALKIAKVALKAL,KIAKVALKALKIAKVALKAL{ct:Amid},DiPGLa-H [PG2],Amidation,Free,Linear,L,None,20,"Antimicrobial, Anticancer",10 % Hemolysis at 3 µM,Human,Template From Pgla-H Xenopus Laevis,Helical,NA,CCTTTGGGTTTGGGTTTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
11332,32752241,2020,KIAKVALKALKIAKGALKAL,KIAKVALKALKIAKGALKAL{ct:Amid},Kiadin-1 [KIA1],Amidation,Free,Linear,L,None,20,"Antimicrobial, Anticancer",10 % Hemolysis at 3 µM,Human,Template From Pgla-H Xenopus Laevis,Helical,NA,CHHHHTHHHHHHHHHHHTTTCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O
11333,32752241,2020,KIGKKILKALKGALKELA,KIGKKILKALKGALKELA{ct:Amid},Mapegin [MAPA],Amidation,Free,Linear,L,None,18,"Antimicrobial, Anticancer",10 % Hemolysis at 1.7 µM,Human,Syntheitc Cell-Penetrating Peptide,Helical,NA,CTHHHHHHTTCSSSSCCCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O
11334,32752241,2020,IDWKKLLDAAKQIL,IDWKKLLDAAKQIL{ct:Amid},Polybia-MP1 [MP1],Amidation,Free,Linear,L,None,14,"Antimicrobial, Anticancer",10 % Hemolysis at 20 µM,Human,Synthetic Amps,Helical,NA,CHHHHHHHHHHHHHHHHTTTCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC
11335,32752241,2020,HHWRRYARIGFRAVRTVIGK,HHWRRYARIGFRAVRTVIGK{ct:Amid},Trichoplaxin-2 [T2],Amidation,Free,Linear,L,None,20,"Antimicrobial, Anticancer",20 % Hemolysis at 3 µM,Human,Phylum Placozo Trichoplax Adhaerens,Helical,NA,CHHHHTHHHHGGGTSCSSSSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C)[C@@H](C)O)C(C)C
11336,32752241,2020,RHHWRRYARIGFRAVRTVIGK,RHHWRRYARIGFRAVRTVIGK{ct:Amid},Trichoplaxin-2A [T2R1],Amidation,Free,Linear,L,None,21,"Antimicrobial, Anticancer",20 % Hemolysis at 25 µM,Human,Analog Of Trichoplaxin-2,Helical,NA,CCTTCGGGTCCTHHHHGGGC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C)[C@@H](C)O)C(C)C
11337,32752241,2020,GIKKAVGKALKGLKGLLKALGES,GIKKAVGKALKGLKGLLKALGES{ct:Amid},Adepantin-1A [A1A],Amidation,Free,Linear,L,None,23,"Antimicrobial, Anticancer",20 % Hemolysis at 80 µM,Human,Adepantin-1 Analog,Helical,NA,CCCSSCTTTCTTTSTTTTTC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)C(C)C
11338,32752241,2020,GIGKFLKKAKKFGKAFVLILKK,GIGKFLKKAKKFGKAFVLILKK{ct:Amid},Pexiganan-L18 [PEXA],Amidation,Free,Linear,L,None,22,"Antimicrobial, Anticancer",20 % Hemolysis at 7 µM,Human,Pexiganan Analog,Helical,NA,CGGGGGHHHHTTTTTTCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C
11339,32752241,2020,GIKKWVKGVAKGVAKDLAKKIL,GIKKWVKGVAKGVAKDLAKKIL{ct:Amid},Flexampin [FLEX],Amidation,Free,Linear,L,None,22,"Antimicrobial, Anticancer",20 % Hemolysis at 25 µM,Human,Template From Ranatuerin-2Csa,Helical,NA,CCHHHHHHHHTTTC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)C(C)C)C(C)C)C(C)C
11340,32752241,2020,GIGREIIKKIIKKIGKKIGRII,GIGREIIKKIIKKIGKKIGRII{ct:Amid},Zyk-1 [ZYK1],Amidation,Free,Linear,L,None,22,"Antimicrobial, Anticancer",20 % Hemolysis at 8 µM,Human,Zyk Strain Of Bacillus Oryziterrae Peptide,Helical,NA,CTTTTTSTHHHHGGGTCC,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(=O)O
11341,32752241,2020,KIAKVALKALKIAKVALKAL,KIAKVALKALKIAKVALKAL{ct:Amid},DiPGLa-H [PG2],Amidation,Free,Linear,L,None,20,"Antimicrobial, Anticancer",20 % Hemolysis at 14 µM,Human,Template From Pgla-H Xenopus Laevis,Helical,NA,CCTTTGGGTTTGGGTTTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
11342,32752241,2020,KIAKVALKALKIAKGALKAL,KIAKVALKALKIAKGALKAL{ct:Amid},Kiadin-1 [KIA1],Amidation,Free,Linear,L,None,20,"Antimicrobial, Anticancer",20 % Hemolysis at 6 µM,Human,Template From Pgla-H Xenopus Laevis,Helical,NA,CHHHHTHHHHHHHHHHHTTTCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O
11343,32752241,2020,KIGKKILKALKGALKELA,KIGKKILKALKGALKELA{ct:Amid},Mapegin [MAPA],Amidation,Free,Linear,L,None,18,"Antimicrobial, Anticancer",20 % Hemolysis at 3 µM,Human,Syntheitc Cell-Penetrating Peptide,Helical,NA,CTHHHHHHTTCSSSSCCCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O
11344,32752241,2020,IDWKKLLDAAKQIL,IDWKKLLDAAKQIL{ct:Amid},Polybia-MP1 [MP1],Amidation,Free,Linear,L,None,14,"Antimicrobial, Anticancer",20 % Hemolysis at 37 µM,Human,Synthetic Amps,Helical,NA,CHHHHHHHHHHHHHHHHTTTCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC
11345,32752241,2020,HHWRRYARIGFRAVRTVIGK,HHWRRYARIGFRAVRTVIGK{ct:Amid},Trichoplaxin-2 [T2],Amidation,Free,Linear,L,None,20,"Antimicrobial, Anticancer",50 % Hemolysis at 28 µM,Human,Phylum Placozo Trichoplax Adhaerens,Helical,NA,CHHHHTHHHHGGGTSCSSSSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C)[C@@H](C)O)C(C)C
11346,32752241,2020,RHHWRRYARIGFRAVRTVIGK,RHHWRRYARIGFRAVRTVIGK{ct:Amid},Trichoplaxin-2A [T2R1],Amidation,Free,Linear,L,None,21,"Antimicrobial, Anticancer",50 % Hemolysis at 7000 µM,Human,Analog Of Trichoplaxin-2,Helical,Low hemolytic,CCTTCGGGTCCTHHHHGGGC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C)[C@@H](C)O)C(C)C
11347,32752241,2020,GIKKAVGKALKGLKGLLKALGES,GIKKAVGKALKGLKGLLKALGES{ct:Amid},Adepantin-1A [A1A],Amidation,Free,Linear,L,None,23,"Antimicrobial, Anticancer",50 % Hemolysis at 125 µM,Human,Adepantin-1 Analog,Helical,NA,CCCSSCTTTCTTTSTTTTTC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)C(C)C
11348,32752241,2020,GIGKFLKKAKKFGKAFVLILKK,GIGKFLKKAKKFGKAFVLILKK{ct:Amid},Pexiganan-L18 [PEXA],Amidation,Free,Linear,L,None,22,"Antimicrobial, Anticancer",50 % Hemolysis at 520 µM,Human,Pexiganan Analog,Helical,NA,CGGGGGHHHHTTTTTTCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C
11349,32752241,2020,GIKKWVKGVAKGVAKDLAKKIL,GIKKWVKGVAKGVAKDLAKKIL{ct:Amid},Flexampin [FLEX],Amidation,Free,Linear,L,None,22,"Antimicrobial, Anticancer",50 % Hemolysis at 1600 µM,Human,Template From Ranatuerin-2Csa,Helical,Low hemolytic,CCHHHHHHHHTTTC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)C(C)C)C(C)C)C(C)C
11350,32752241,2020,GIGREIIKKIIKKIGKKIGRII,GIGREIIKKIIKKIGKKIGRII{ct:Amid},Zyk-1 [ZYK1],Amidation,Free,Linear,L,None,22,"Antimicrobial, Anticancer",50 % Hemolysis at 29 µM,Human,Zyk Strain Of Bacillus Oryziterrae Peptide,Helical,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(=O)O
11351,32752241,2020,KIAKVALKALKIAKVALKAL,KIAKVALKALKIAKVALKAL{ct:Amid},DiPGLa-H [PG2],Amidation,Free,Linear,L,None,20,"Antimicrobial, Anticancer",50 % Hemolysis at 18 µM,Human,Template From Pgla-H Xenopus Laevis,Helical,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
11352,32752241,2020,KIAKVALKALKIAKGALKAL,KIAKVALKALKIAKGALKAL{ct:Amid},Kiadin-1 [KIA1],Amidation,Free,Linear,L,None,20,"Antimicrobial, Anticancer",50 % Hemolysis at 20 µM,Human,Template From Pgla-H Xenopus Laevis,Helical,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O
11353,32752241,2020,KIGKKILKALKGALKELA,KIGKKILKALKGALKELA{ct:Amid},Mapegin [MAPA],Amidation,Free,Linear,L,None,18,"Antimicrobial, Anticancer",50 % Hemolysis at 20 µM,Human,Syntheitc Cell-Penetrating Peptide,Helical,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O
11354,32752241,2020,IDWKKLLDAAKQIL,IDWKKLLDAAKQIL{ct:Amid},Polybia-MP1 [MP1],Amidation,Free,Linear,L,None,14,"Antimicrobial, Anticancer",50 % Hemolysis at 170 µM,Human,Synthetic Amps,Helical,NA,NA,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC
11355,32764602,2020,K-K-L-K-(2-Nal)Ala-F-(2-Nal-)Ala,K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala},1,Free,Free,Linear,L,(2-Nal)Ala = 2-napthylalanine,7,"Antibacterial, Anticancer",<8 % Hemolysis at 150 µM,Human,Synthetic Amps,NA,Low hemolytic,NA,NA
11356,32764602,2020,(N1-Nal)Gly-(N-Phe)Gly-(N1-Nal)Gly-(N-Bu)Gly-K-K-K,{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K,2,Free,Free,Linear,L,"(N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine",7,"Antibacterial, Anticancer",78.1 % Hemolysis at 150 µM,Human,Synthetic Amps,NA,NA,NA,NA
11358,32764602,2020,(2-nal)ala-f-(2-nal)ala-l-K-K-K,{nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K,4,Free,Free,Linear,Mix,"(2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu",7,"Antibacterial, Anticancer",<8 % Hemolysis at 150 µM,Human,Synthetic Amps,NA,Low hemolytic,NA,NA
11359,32764602,2020,(1-Nal)Ala-F-(1-Nal)Ala-L-K-K-K,{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K,5,Free,Free,Linear,L,(1-Nal)Ala = 1-napthylalanine,7,"Antibacterial, Anticancer",36 % Hemolysis at 150 µM,Human,Synthetic Amps,NA,NA,NA,NA
11365,32764602,2020,K-K-K-l-(1-nal)ala-f-(1-nal)ala,K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala},11,Free,Free,Linear,Mix,"(1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu",7,"Antibacterial, Anticancer",33.3 % Hemolysis at 150 µM,Human,Synthetic Amps,NA,NA,NA,NA
11369,32764602,2020,K-K-K-(N-Bu)Gly-(N1-Nal)Gly-(N-Phe)Gly-(N1-Nal)Gly,K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly},15,Free,Free,Linear,L,"(N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine",7,"Antibacterial, Anticancer",94.2 % Hemolysis at 150 µM,Human,Synthetic Amps,NA,NA,NA,NA
11379,32764602,2020,K-K-L-K-(2-Nal)Ala-F-(2-Nal-)Ala,K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala},1,Free,Free,Linear,L,(2-Nal)Ala = 2-napthylalanine,7,"Antibacterial, Anticancer",19.7 % Hemolysis at 150 µM,Canine,Synthetic Amps,NA,NA,NA,NA
11380,32764602,2020,(N1-Nal)Gly-(N-Phe)Gly-(N1-Nal)Gly-(N-Bu)Gly-K-K-K,{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K,2,Free,Free,Linear,L,"(N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine",7,"Antibacterial, Anticancer",100.1 % Hemolysis at 150 µM,Canine,Synthetic Amps,NA,NA,NA,NA
11382,32764602,2020,(2-nal)ala-f-(2-nal)ala-l-K-K-K,{nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K,4,Free,Free,Linear,Mix,"(2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu",7,"Antibacterial, Anticancer",<8 % Hemolysis at 150 µM,Canine,Synthetic Amps,NA,Low hemolytic,NA,NA
11383,32764602,2020,(1-Nal)Ala-F-(1-Nal)Ala-L-K-K-K,{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K,5,Free,Free,Linear,L,(1-Nal)Ala = 1-napthylalanine,7,"Antibacterial, Anticancer",22.5 % Hemolysis at 150 µM,Canine,Synthetic Amps,NA,NA,NA,NA
11389,32764602,2020,K-K-K-l-(1-nal)ala-f-(1-nal)ala,K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala},11,Free,Free,Linear,Mix,"(1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu",7,"Antibacterial, Anticancer",40.7 % Hemolysis at 150 µM,Canine,Synthetic Amps,NA,NA,NA,NA
11393,32764602,2020,K-K-K-(N-Bu)Gly-(N1-Nal)Gly-(N-Phe)Gly-(N1-Nal)Gly,K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly},15,Free,Free,Linear,L,"(N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine",7,"Antibacterial, Anticancer",87.1 % Hemolysis at 150 µM,Canine,Synthetic Amps,NA,NA,NA,NA
11403,32764602,2020,K-K-L-K-(2-Nal)Ala-F-(2-Nal-)Ala,K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala},1,Free,Free,Linear,L,(2-Nal)Ala = 2-napthylalanine,7,"Antibacterial, Anticancer",<8 % Hemolysis at 150 µM,Rat,Synthetic Amps,NA,Low hemolytic,NA,NA
11404,32764602,2020,(N1-Nal)Gly-(N-Phe)Gly-(N1-Nal)Gly-(N-Bu)Gly-K-K-K,{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K,2,Free,Free,Linear,L,"(N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine",7,"Antibacterial, Anticancer",100 % Hemolysis at 150 µM,Rat,Synthetic Amps,NA,NA,NA,NA
11406,32764602,2020,(2-nal)ala-f-(2-nal)ala-l-K-K-K,{nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K,4,Free,Free,Linear,Mix,"(2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu",7,"Antibacterial, Anticancer",<8 % Hemolysis at 150 µM,Rat,Synthetic Amps,NA,Low hemolytic,NA,NA
11407,32764602,2020,(1-Nal)Ala-F-(1-Nal)Ala-L-K-K-K,{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K,5,Free,Free,Linear,L,(1-Nal)Ala = 1-napthylalanine,7,"Antibacterial, Anticancer",10.2 % Hemolysis at 150 µM,Rat,Synthetic Amps,NA,NA,NA,NA
11413,32764602,2020,K-K-K-l-(1-nal)ala-f-(1-nal)ala,K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala},11,Free,Free,Linear,Mix,"(1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu",7,"Antibacterial, Anticancer",11.3 % Hemolysis at 150 µM,Rat,Synthetic Amps,NA,NA,NA,NA
11417,32764602,2020,K-K-K-(N-Bu)Gly-(N1-Nal)Gly-(N-Phe)Gly-(N1-Nal)Gly,K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly},15,Free,Free,Linear,L,"(N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine",7,"Antibacterial, Anticancer",99.5 % Hemolysis at 150 µM,Rat,Synthetic Amps,NA,NA,NA,NA
11427,32764602,2020,K-K-L-K-(2-Nal)Ala-F-(2-Nal-)Ala,K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala},1,Free,Free,Linear,L,(2-Nal)Ala = 2-napthylalanine,7,"Antibacterial, Anticancer",32.5 % Hemolysis at 150 µM,Bovine,Synthetic Amps,NA,NA,NA,NA
11428,32764602,2020,(N1-Nal)Gly-(N-Phe)Gly-(N1-Nal)Gly-(N-Bu)Gly-K-K-K,{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K,2,Free,Free,Linear,L,"(N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine",7,"Antibacterial, Anticancer",<8 % Hemolysis at 150 µM,Bovine,Synthetic Amps,NA,Low hemolytic,NA,NA
11430,32764602,2020,(2-nal)ala-f-(2-nal)ala-l-K-K-K,{nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K,4,Free,Free,Linear,Mix,"(2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu",7,"Antibacterial, Anticancer",<8 % Hemolysis at 150 µM,Bovine,Synthetic Amps,NA,Low hemolytic,NA,NA
11431,32764602,2020,(1-Nal)Ala-F-(1-Nal)Ala-L-K-K-K,{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K,5,Free,Free,Linear,L,(1-Nal)Ala = 1-napthylalanine,7,"Antibacterial, Anticancer",<8 % Hemolysis at 150 µM,Bovine,Synthetic Amps,NA,Low hemolytic,NA,NA
11437,32764602,2020,K-K-K-l-(1-nal)ala-f-(1-nal)ala,K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala},11,Free,Free,Linear,Mix,"(1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu",7,"Antibacterial, Anticancer",17.4 % Hemolysis at 150 µM,Bovine,Synthetic Amps,NA,NA,NA,NA
11441,32764602,2020,K-K-K-(N-Bu)Gly-(N1-Nal)Gly-(N-Phe)Gly-(N1-Nal)Gly,K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly},15,Free,Free,Linear,L,"(N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine",7,"Antibacterial, Anticancer",<8 % Hemolysis at 150 µM,Bovine,Synthetic Amps,NA,Low hemolytic,NA,NA
11549,32967114,2020,FIGTLIPLALGALTKLFK,FIGTLIPLALGALTKLFK{ct:Amid},Figainin 1,Amidation,Free,Linear,L,None,18,"Antibacterial, Anticancer, Anti-infective, Antitrypanosomal",50 % Hemolysis at 10 µM,Human,Frog Boana Raniceps,"water and 10% (v/v) TFE = Disordered, 30% (v/v) and 50% (v/v) TFE = α-Helical",NA,CCSCSSSHHHHHHHCCC,CC[C@H](C)[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O
11600,33063186,2020,FKLVWKLLKKLALKL,FKLVWKLLKKLALKL,Aper1,Free,Free,Linear,L,None,15,"Anticancer, Antimicrobial",10 % Hemolysis at 5.96 µM,Human,Derived From The Thermophilic Bacteria Aeropyrum Pernix.,NA,NA,CTHHHHSCCC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(=O)O
11797,33669976,2021,Methyldecanoyl-MePro-AHMOD-A-Aib-I-Iva-βAla-Alaol-Glyol,{nnr:Methyldecanoyl}-{nnr:MePro}-{nnr:AHMOD}-A-{nnr:Aib}-I-{nnr:Iva}-{nnr:βAla}-Alaol-{nnr:Glyol}{nt:amino group}{ct:hydroxyl},EmiA,hydroxyl,amino group,Linear,L,"MePro = Methylproline, AHMOD = 2-Amino-3-hydroxy-4-methyl-2-pentenoic acid, Aib = α-Amino isobutyric acid, Iva = Isovaline, βAla = β-Alanine{nnr:Bala} – β-Alanine , Glyol = Glycine with a hydroxyl modification, Methyldecanoyl = Methyldecanoyl",9,"Antifungal, Anticancer",12.6 % Hemolysis at 20 µM,Human,Derived From The Alkalophilic Fungus Emericellopsis Alkalina,NA,NA,NA,NA
11830,33582221,2021,ALWKDLLKNVGIAAGKAALNKVTDMVNQ,ALWKDLLKNVGIAAGKAALNKVTDMVNQ{ct:Amid},DRS-TO,Amidation,Free,Linear,L,None,28,"Anticancer, Antimicrobial",50 % Hemolysis at 436.7 µM,Horse,Leaf Frog Phyllomedusa Tomopterna,Helical,Low hemolytic,CCCHHHHHHHHHHHHTTTCC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O)C(C)C)[C@@H](C)O)C(C)C
11843,33244888,2021,IFWLFRGKADVAL,IFWLFRGKADVAL{ct:Amid},neuroVAL,Amidation,Free,Linear,L,None,13,"Anticancer, Antimicrobial",50 % Hemolysis at >64 µM,Human,Agelaia-Mpi Analogues,30% TFE = α-Helical,Low hemolytic,CCCCCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
11844,33244888,2021,ILGTILGLLKGL,ILGTILGLLKGL{ct:Amid},protonectin,Amidation,Free,Linear,L,None,12,"Anticancer, Antimicrobial",50 % Hemolysis at >64 µM,Human,Wasp Parachartergus Fraternus,30% TFE = α-Helical,Low hemolytic,CCCTHHHHTTSSSSCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)O
11845,33244888,2021,IFGTILGFLKGL,IFGTILGFLKGL{ct:Amid},protonectin-F,Amidation,Free,Linear,L,None,12,"Anticancer, Antimicrobial",50 % Hemolysis at >64 µM,Human,Protonectin Analogues,30% TFE = α-Helical,Low hemolytic,CCCSSHHHHTGGGGSCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)O
12319,34508563,2021,FLGALFKVASKLVPAAICSISKKC,FLGALFKVASKLVPAAICSISKKC,Brevinin-1HL,Free,Free,Linear,L,None,24,"Antimicrobial, Anticancer, Antibiofilm",50 % Hemolysis at 11.5 ± 0.2 µM,Horse,"Broad-Folded Frog, Hylarana Latouchii","aqueous = Random coil, 50% TFE = α-Helical",NA,CTHHHHHHHHHHHHTTC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)CC
12320,34508563,2021,FFPLIFGALSSILPKIL,FFPLIFGALSSILPKIL,Temporin-HLa,Free,Free,Linear,L,None,17,"Antimicrobial, Anticancer, Antibiofilm",50 % Hemolysis at 31.4 ± 0.7 µM,Horse,"Broad-Folded Frog, Hylarana Latouchii","aqueous = Random coil, 50% TFE = α-Helical",NA,CTHHHHHHHHHHHHTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O
12321,34508563,2021,FLQHIIGALSHIF,FLQHIIGALSHIF,Temporin-HLb,Free,Free,Linear,L,None,13,"Antimicrobial, Anticancer, Antibiofilm",50 % Hemolysis at 18.6 ± 10.0 mM,Horse,"Broad-Folded Frog, Hylarana Latouchii","aqueous = Random coil, 50% TFE = α-Helical",Low hemolytic,CTHHHHHHHHHHHHTTC,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
12356,34867962,2021,FLPLLISALTSLFPKLGK,FLPLLISALTSLFPKLGK,SSTP1,Free,Free,Linear,L,None,18,Anticancer,0.25 % Hemolysis at 5 µM,Human,Frog Indosylvirana Aurantiaca Host Defense Peptide,NA,Low hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)O
12391,34941705,2021,ASIGALIQKAIALIKAKAA,ASIGALIQKAIALIKAKAA{nt:Amid}{ct:Amid},LVTX-9,Amidation,Amidation,Linear,L,None,19,Anticancer,0 % Hemolysis at 200 µM,Human,Venom Gland Of The Spider Lycosa Vittata,"ultrapure water = Random coil, SDS = α-Helical",Non-hemolytic,CTHHHHTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)N)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)[C@@H](C)CC
12392,34941705,2021,ASIGALIQKAIALIKAKAA,ASIGALIQKAIALIKAKAA{nt:CH3-(CH2)16CONH}{ct:Amid},LVTX-9-C18,Amidation,CH3-(CH2)16CONH,Linear,L,CH3-(CH2)16 = N-Terminal Fatty acid,23,Anticancer,10 % Hemolysis at 25 µM,Human,"Lvtx-9, Fatty Acid Modification","ultrapure water = α-Helical, SDS = α-Helical",NA,NA,NA
12413,34796903,2021,PARDVLNTTSG,PARDVLNTTSG{ct:Amid},P264-G274,Amidation,Free,Linear,L,None,11,Anticancer,12.2 % Hemolysis at 150 µM,Sheep,Toxin Ps2Aa1 Parasporin-2Aa1,α-Helix,NA,CTHHHHHHHHCGGGHHHHCSSCTTCC,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)[C@@H](C)O)[C@@H](C)O
12414,34796903,2021,NNETYFNAVKP,NNETYFNAVKP{ct:Amid},Loop1-PS2Aa,Amidation,Free,Linear,L,None,11,Anticancer,18.1 % Hemolysis at 150 µM,Sheep,Toxin Ps2Aa1 Parasporin-2Aa1,α-Helix,NA,CTHHHHHHHHCGGGHHHHCSSCTTCC,CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O
12415,34796903,2021,TYFNAVKPPITA,TYFNAVKPPITA{ct:Amid},Loop2-PS2Aa,Amidation,Free,Linear,L,None,12,Anticancer,9.4 % Hemolysis at 150 µM,Sheep,Toxin Ps2Aa1 Parasporin-2Aa1,α-Helix,NA,CTHHHHHHHHCGGGHHHHCSSCTTCC,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)[C@@H](C)O)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)O)[C@@H](C)O
12416,34796903,2021,FKPQSGGGKCF,FKPQSGGGKCF{ct:Amid},Loop1-HCoV-229E,Amidation,Free,Linear,L,None,11,Anticancer,9.2 % Hemolysis at 150 µM,Sheep,Spike Protein Of The Alphacoronavirus Hcov-229E,β-lSheet,NA,CTHHHHHHHHCGGGHHHHCSSCTTCC,NCCCC[C@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
12417,34796903,2021,FLGWLFKVASK,FLGWLFKVASK{ct:Amid},A4W-GGN5,Amidation,Free,Linear,L,None,11,"Antimicrobial, Anticancer",23 % Hemolysis at 150 µM,Sheep,Na,NA,NA,CCHHHHTTTTTCCC,CC(C)C[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C
12499,35100952,2022,KFVRSRRPRTASCALAFVN,KFVRSRRPRTASCALAFVN,ARF (26-44),Free,Free,Linear,L,None,19,"Antibacterial, Anticancer",5 % Hemolysis at 250 µM,Mouse,Arf(Alternative Reading Frame) Proteins Are P19Arf In Mice,"phosphate buffer = Random coil, 50% v/v TFE = α-Helix",Low hemolytic,CTTHHHHHHHHHHHHHGGGGTCC,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C
12545,36465844,2022,GVKFAKRFWRFAKKAFKRFEK,GVKFAKRFWRFAKKAFKRFEK{nt:Amid},HAZ,Free,Amidation,Linear,L,None,21,"Antibacterial, Antibiofilm, Anticancer",20 % Hemolysis at 120 µM,Human,Synthetic Hybride (Palustrin-1D And Hp(2–20)) Peptide,α-Helical,NA,CTTCCCSSTTCGGGGHHHHHHHC,CC(C)[C@H](NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O
12673,36279986,2022,"β2,2-Ac6c-Gpn-β2,2-Ac6c-Gpn-β2,2-Ac6c-Gpn","{nnr:β2,2-Ac6c}-{nnr:Gpn}-{nnr:β2,2-Ac6c}-{nnr:Gpn}-{nnr:β2,2-Ac6c}-{nnr:Gpn}{nt:H}{ct:OMe}",BG6,OMe,H,Linear,NA,"β2,2-Ac6c = 1-aminomethylcyclohexane carboxylic acid, Gpn = 2-(1-(aminomethyl)cyclohexyl)acetic acid",6,"Anticancer, Anti-migratory and Anti-invasive",8.05 % Hemolysis at 30 µM/ml,Human,Short Hybrid Synthetic Peptide,NA,Low hemolytic,NA,NA
12676,36336133,2022,GLFDIIKKIAESF,GLFDIIKKIAESF,Aurein 1.2,Free,Free,Linear,L,None,13,"Antimicrobial, Anticancer",>20 % Hemolysis at 500 μg/ml,Human,"Skin Of Australian Bell Frogs, Ranoidea Aurea (Formerly Litoria Aurea) And R. Raniformis (Formerly L. Raniformis)",α-Helix,NA,CCHHHHHHHHTTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
12679,36336133,2022,GLFDIIKKIAESF,GLFDIIKKIAESF,Aurein 1.2,Free,Free,Linear,L,None,13,"Antimicrobial, Anticancer",<35 % Hemolysis at 1000 μg/ml,Human,"Skin Of Australian Bell Frogs, Ranoidea Aurea (Formerly Litoria Aurea) And R. Raniformis (Formerly L. Raniformis)",α-Helix,NA,CCTTTCHIIIIIITC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
12690,36555393,2022,VLTTGLPALISWIKRKRQQGGGGSklaklakklaklak,VLTTGLPALISWIKRKRQQGGGGSK{d}L{d}A{d}K{d}L{d}A{d}K{d}K{d}L{d}A{d}K{d}L{d}A{d}K{d}{nt:(FITC)-Ahx = Fluorescein isothiocyanate},melittin-dKLA 8-26,Free,(FITC)-Ahx = Fluorescein isothiocyanate,Linear,Mix,nter = (FITC)-Ahx,38,Anticancer,<5 % Hemolysis at 40 µM,Mouse,Modified Melittin,NA,Non-hemolytic,CCTTTTTTTHHHHGGGGGCC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC
12699,36668862,2023,LLKKVLALLKKVL,LLKKVLALLKKVL{nt:Amid},Hp-MAP3,Free,Amidation,Linear,L,None,13,"Antibacterial, Antibiofilm, Antifungal, Anticancer",~15 % Hemolysis at 10.8 µM,mouse,Temporin-Pta Analog,50% TFE or SDS = α-Helix,NA,CCCCCSGGGTTTCCC,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(C)C)C(C)C)C(=O)O
12700,36668862,2023,LLKKVLALLKKVL,LLKKVLALLKKVL{nt:Amid},Hp-MAP3,Free,Amidation,Linear,L,None,13,"Antibacterial, Antibiofilm, Antifungal, Anticancer",25 % Hemolysis at 21.6 µM,mouse,Temporin-Pta Analog,50% TFE or SDS = α-Helix,NA,CCSSCCCTTTTTTCCTTSSSTTSBSSSBC,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(C)C)C(C)C)C(=O)O
12701,36668862,2023,LLKKVLALLKKVL,LLKKVLALLKKVL{nt:Amid},Hp-MAP3,Free,Amidation,Linear,L,None,13,"Antibacterial, Antibiofilm, Antifungal, Anticancer",~85 % Hemolysis at 43.3 µM,mouse,Temporin-Pta Analog,50% TFE or SDS = α-Helix,NA,CCSGGGGGHHHHHHHTTCCC,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(C)C)C(C)C)C(=O)O
12722,36910465,2023,KLWCKSSQVPQSR,KLWCKSSQVPQSR,ALA‐A2,Free,Free,Linear,L,None,13,Anticancer,7.8 ± 10.2 % Hemolysis at 200 µM,Human,Synthetic Peptide Sequence Of Alphalactalbumin,Helix–coil,Low hemolytic,CGGGTTTTTTSSTTC,CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C
12725,36910465,2023,FKCRRWQWRMKKLGAPSITCVR,FKCRRWQWRMKKLGAPSITCVR,"BMP‐S6 (positive control)[ 5 , 10 ]",Free,Free,Linear,L,None,22,Anticancer,6.0± 9.2 % Hemolysis at 200 µM,Human,Bovine-Derived Acp,coil–Helix,Low hemolytic,CCCSSGGGGTSCSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C)[C@@H](C)O
12822,37310533,2023,RIIDRLWLVRRPQKPKFVLVWVL,RIIDRLWLVRRPQKPKFVLVWVL,PMAP-NC,Free,Free,Linear,L,None,23,"Antibacterial, Anticancer",20 % Hemolysis at 64 µM,Human,Pmap-23 Analogs,Helix–hinge–Helix,NA,CC,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)CC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C)C(C)C)C(C)C)C(C)C
12844,36907048,2023,IWLTALKFLGKNLGKHLAKQQLSKL,IWLTALKFLGKNLGKHLAKQQLSKL{nt:H}{ct:Amid},LVTX-8,Amidation,H,Linear,L,None,25,Anticancer,66.7 % Hemolysis at >5 µM,Human,Spider Lycosa Vittata,PBS buffer = α-Helical,NA,CCCSBTTBCCCCCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)O
12845,36907048,2023,IWLTALKFLGKNLGKHLAKQQLSKL,IWLTALKFLGKNLGKHLAKQQLSKL{nt:hydrazide = NHNH2}{ct:Acet},825,Acetylation,hydrazide = NHNH2,Linear,L,None,25,Anticancer,16.7 % Hemolysis at >5 µM,Human,Lvtx-8-Analogs,PBS buffer = α-Helical,Low hemolytic,CCCHHHHTTGGGTTSCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)O
12846,36907048,2023,GFLG-IWLTALKFLGKNLGKHLAKQQLSKL,GFLG-IWLTALKFLGKNLGKHLAKQQLSKL{nt:MTX}{ct:Amid},827,Amidation,MTX,Linear,L,MTX = methotrexate,29,Anticancer,35.8 % Hemolysis at >5 µM,Human,Lvtx-8-Analogs,PBS buffer = α-Helical,NA,NA,NA
12897,25626077,2015,FLFKLIPKVIKGLVKAIRK,FLFKLIPKVIKGLVKAIRK{ct:Amid},AaeAP1a,Amidation,Free,Linear,L,None,19,"Antibacterial, Antifungal. Anticancer, Antiproliferative",100 % Hemolysis at 32 μg/ml,Horse,Aaeap1 Analogues,31.58% α-Helix,NA,CTTTTTCTTGGGCCCHHHHCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O
12898,25626077,2015,FLFKLIPKAIKGLVKAIRK,FLFKLIPKAIKGLVKAIRK{ct:Amid},AaeAP2a,Amidation,Free,Linear,L,None,19,"Antibacterial, Antifungal. Anticancer, Antiproliferative",100 % Hemolysis at 64 μg/ml,Horse,Aaeap2 Analogues,31.58% α-Helix,NA,CCCCCCSSCSSTTTCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C
13102,35606468,2022,GLLGKILGAGKKVLCGVSGLC,GLLGKILGAGKKVLCGVSGLC,Nigrocin-PN,Free,Free,Linear,L,None,21,"Antimicrobial, Anticancer",0 % Hemolysis at 10 µM,Horse,Pelophylax Nigromaculatus,Random coil,Non-hemolytic,CGGGGGTTTTTTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)C(C)C)C(C)C
13103,35606468,2022,GLLGKILGAGKKVLCGVSGLC,GLLGKILGAGKKVLCGVSGLC,Nigrocin-PN,Free,Free,Linear,L,None,21,"Antimicrobial, Anticancer",<5 % Hemolysis at 100 µM,Horse,Pelophylax Nigromaculatus,Random coil,Non-hemolytic,CCHHHHHHHHTTSSTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)C(C)C)C(C)C
13104,35606468,2022,GLLGKILGAGKKVLLGVSGLL,GLLGKILGAGKKVLLGVSGLL,Nigrocin-M1,Free,Free,Linear,L,None,21,"Antimicrobial, Anticancer",0 % Hemolysis at 10 µM,Horse,Pelophylax Nigromaculatus,Random coil,Non-hemolytic,CCTHHHHHHHTTSSTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C)C(C)C
13105,35606468,2022,GLLGKILGAGKKVLLGVSGLL,GLLGKILGAGKKVLLGVSGLL,Nigrocin-M1,Free,Free,Linear,L,None,21,"Antimicrobial, Anticancer",<20 % Hemolysis at 100 µM,Horse,Pelophylax Nigromaculatus,Random coil,Non-hemolytic,CCCCCGGGGTCCCGGGC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C)C(C)C
13106,35606468,2022,GLLGKILGAGKKVL,GLLGKILGAGKKVL,Nigrocin-M2,Free,Free,Linear,L,None,14,"Antimicrobial, Anticancer",0 % Hemolysis at 10 µM,Horse,Pelophylax Nigromaculatus,Random coil,Non-hemolytic,CCTHHHHHHHTTSSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
13107,35606468,2022,GLLGKILGAGKKVL,GLLGKILGAGKKVL,Nigrocin-M2,Free,Free,Linear,L,None,14,"Antimicrobial, Anticancer",0 % Hemolysis at 100 µM,Horse,Pelophylax Nigromaculatus,Random coil,Non-hemolytic,CCHHHHHHHHHHSCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
13775,25561178,2015,xISqiIStAXI,{nnr:x}ISQ{d}I{d}IST{d}A{nnr:X}I,Teixobactin,Free,Free,Linear,Mix,"x = NmPhe(N-methylated phenylalanine), X = End (Enduracididine)",11,"Anticancer, Antibacterial",No Hemolysis,Human,Eleftheria Terrae,NA,Non-hemolytic,NA,NA
13812,11835991,2002,GIGTKILGGVKTALKGALKELASTYAN,GIGTKILGGVKTALKGALKELASTYAN{ct:Amid},Maximin 1,Amidation,Free,Linear,L,None,27,"Antibacterial, Antiviral, Antifungal, candidacidal, Spermicidal, Anti-HIV, Hemolytic, Anticancer",Low Hemolysis at 50 μg/ml,Rabbit,"Chinese Red Belly Toad, Bombina Maxima",Helix,Low hemolytic,CCCCHHHHHHHHHHCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)CC)[C@@H](C)O
13844,19254736,2009,FLPAIVGAAAKFLPKIFCAISKKC,FLPAIVGAAAKFLPKIFCAISKKC,Brevinin-1BLa,Free,Free,Linear,L,None,24,"Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer",50 % Hemolytic at 14 µM,Human,"Leopard Frog, Lithobates Yavapaiensis, North America",NA,NA,CCCCTHHHHHHHHHHHHHHHTTCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O
13845,19254736,2009,FLPIIAGVAAKVLPKIFCAISKKC,FLPIIAGVAAKVLPKIFCAISKKC,Brevinin-1BLb,Free,Free,Linear,L,None,24,"Antibacterial, Antifungal, Hemolytic, Anticancer",Hemolytic,Human,"Leopard Frog, Lithobates Yavapaiensis, North America",NA,NA,CCTTCBCSSSSCSBSSSSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)[C@@H](C)CC)C(C)C)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O
13846,19254736,2009,FLPIIAGIAAKFLPKIFCTISKKC,FLPIIAGIAAKFLPKIFCTISKKC,Brevinin-1BLc,Free,Free,Linear,L,None,24,"Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer",50 % Hemolytic at 9 µM,Human,"Leopard Frog, Lithobates Yavapaiensis, North America",NA,NA,CCCCCSCSTTTTSSSCCSCC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC
13847,19254736,2009,FLPVIAGVAANFLPKLFCAISKKC,FLPVIAGVAANFLPKLFCAISKKC,Brevinin-1Ya,Free,Free,Linear,L,None,24,"Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer",50 % Hemolytic at 18 µM,Human,"Leopard Frog, Lithobates Yavapaiensis, North America",NA,NA,CCCSSCCHHHHHHHSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O
13848,19254736,2009,FLPIIAGAAAKVVEKIFCAISKKC,FLPIIAGAAAKVVEKIFCAISKKC,Brevinin-1Yc,Free,Free,Linear,L,None,24,"Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer",50 % Hemolytic at 13 µM,Human,"Leopard Frog, Lithobates Yavapaiensis, North America",NA,NA,CCHHHHHHHHHHHTTTGGGTTTTSSCCSCSSSSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)[C@@H](C)CC)C(C)C)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O
13857,21596752,2011,GIPCGESCVFIPCITGAIGCSCKSKVCYRN,GIPCGESCVFIPCITGAIGCSCKSKVCYRN{cyc:N-C},Cliotide T1,Free,Free,Cyclic,L,None,30,"Antibacterial, Hemolytic, Anticancer",50 % Hemolytic at 7.1 µM,Human,Plant Clitoria Ternatea,NA,NA,CCHHHHTTTCTTCCTHHHHTCCCCCTTSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C
13858,21596752,2011,GLPTCGETCTLGTCYVPDCSCSWPICMKN,GLPTCGETCTLGTCYVPDCSCSWPICMKN{cyc:N-C},Cliotide T3,Free,Free,Cyclic,L,None,29,"Hemolytic, Anticancer",50 % Hemolytic at 13.1 µM,Human,Plant Clitoria Ternatea,NA,NA,CCTHHHHHHHHHSSCCC,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)CN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)O
13859,21596752,2011,GIPCGESCVFIPCITAAIGCSCKSKVCYRN,GIPCGESCVFIPCITAAIGCSCKSKVCYRN{cyc:N-C},Cliotide T4,Free,Free,Cyclic,L,None,30,"Antibacterial, Hemolytic, Anticancer",50 % Hemolytic at 8.4 µM,Human,Plant Clitoria Ternatea,NA,NA,CCCHHHHHHHSCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C
13869,22467870,2012,GDACGETCFTGICFTAGCSCNPWPTCTRN,GDACGETCFTGICFTAGCSCNPWPTCTRN{cyc:N-C},ChaC1 (chassatide C1),Free,Free,Cyclic,L,None,29,"Hemolytic, Anticancer",Hemolytic,Human,Hybrid Peptide,Bridge,NA,CTTTTHHHHHHHHHHHSCGGGTCC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)CN)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O
13870,22467870,2012,GASCGETCFTGICFTAGCSCNPWPTCTRN,GASCGETCFTGICFTAGCSCNPWPTCTRN{cyc:N-C},ChaC4 (chassatide C4),Free,Free,Cyclic,L,None,29,"Hemolytic, Anticancer",Hemolytic,Human,Plant Chassalia Chartacea (Or Chassalia Curviflora),Bridge,NA,CTTTTHHHHHHHHHHHSCGGGTCC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)CN)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O
13871,22467870,2012,IPCGESCVWIPCITAIAGCSCKNKVCYT,IPCGESCVWIPCITAIAGCSCKNKVCYT,ChaC7 (chassatide C7),Free,Free,Linear,L,None,28,"Antibacterial, Hemolytic, Anticancer",50 % Hemolytic at 11.6 µM,Human,Plant Chassalia Chartacea (Or Chassalia Curviflora),Bridge,NA,CTTTTHHHHHHHHHHHSCGGGTCC,CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)O)[C@@H](C)O)C(C)C)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(C)C
13872,22467870,2012,AIPCGESCVWIPCISTVIGCSCSNKVCYR,AIPCGESCVWIPCISTVIGCSCSNKVCYR,ChaC8 (chassatide C8),Free,Free,Linear,L,None,29,"Antibacterial, Hemolytic, Anticancer",50 % Hemolytic at 25.5 µM,Human,Plant Chassalia Chartacea (Or Chassalia Curviflora),Bridge,NA,CHHHHHHHHHHHHHHHHTTSSSCCCSTTSSCCSCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C)[C@@H](C)CC)C(C)C)[C@@H](C)O
13873,22467870,2012,IPCGESCVWIPCISGMFGCSCKDKVCYS,IPCGESCVWIPCISGMFGCSCKDKVCYS,ChaC11 (chassatide C11),Free,Free,Linear,L,None,28,"Antibacterial, Hemolytic, Anticancer",50 % Hemolytic at 13.3 µM,Human,Plant Chassalia Chartacea (Or Chassalia Curviflora),Bridge,NA,CCCBSSGGGGGGGGTTHHHHTTTTCCBCCCC,CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)O)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(C)C
13913,31328553,2021,SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC,SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC{ct:Amid},Esculentin-2 HYba1,Amidation,Free,Linear,L,None,37,"Antibacterial, Anti-MRSA, Hemolytic, Anticancer",50 % Hemolytic at 15 µM,Human,"Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia",NA,NA,CCTHHHHHHHTTHHHHHHTTTTTC,CC[C@H](C)[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)O)[C@@H](C)O
13914,31328553,2021,SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC,SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC{ct:Amid},Esculentin-2 HYba2,Amidation,Free,Linear,L,None,37,"Antibacterial, Anti-MRSA, Hemolytic, Anticancer",50 % Hemolytic at 12 µM,Human,"Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia",NA,NA,CCCCCCCCCCCCCCSCCCCSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)O)C(C)C
13915,31328553,2021,SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC,SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC,Esculentin-2 HYba1,Free,Free,Linear,L,None,37,"Antibacterial, Anti-MRSA, Hemolytic, Anticancer",50 % Hemolytic at 10 µM,Human,"Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia",NA,NA,CCCCCCCCCGGGSSSCCSSCCCC,CC[C@H](C)[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)O)[C@@H](C)O
13916,31328553,2021,SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC,SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC,Esculentin-2 HYba2,Free,Free,Linear,L,None,37,"Antibacterial, Anti-MRSA, Hemolytic, Anticancer",50 % Hemolytic at 10 µM,Human,"Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia",NA,NA,CCCGGGCSSHHHHHTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)O)C(C)C
13948,38611812,2024,FLPLLAGLAASFLPTIFCKISRKC,FLPLLAGLAASFLPTIFCKISRKC{cyc:18-24},Brevinin-1BW,C-terminus contains a Rana box: one disulfide bond.,Free,Linear,L,None,24,"Antibacterial, Anti-inflammatory, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer",50 % Hemolytic at 35.8 μg/ml,Sheep,"Skin, Pelophylax Nigromaculatus, East Asia",NA,NA,CCCCTHHHHTTCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O
13965,39204443,2024,FLSLIPHAISAVSALAKHL,FLSLIPHAISAVSALAKHL,Phylloseptin-TO2,Free,Free,Linear,L,None,19,"Antibacterial, Antifungal, candidacidal, Anti-MRSA, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer",50 % Hemolytic at 64 µM,Horse,"Skin Secretion, Super Tiger Leg Monkey Tree Frog, Phyllomedusa Tomopterna, Central America, South America",Helix,NA,CCCCGGGGTSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
13966,39204443,2024,FLSLIPKAISAVSALAKHL,FLSLIPKAISAVSALAKHL,PSTO2 7K,Free,Free,Linear,L,None,19,"Antibacterial, Antifungal, candidacidal, Anti-MRSA, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer",50 % Hemolytic at 32-64 µM,Horse,Synthetic Peptide,Helix,NA,CCHHHHHHHHHHC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
13967,39204443,2024,FLSLIPKAISAVSALAKKL,FLSLIPKAISAVSALAKKL,PSTO2 18K,Free,Free,Linear,L,None,19,"Antibacterial, Antifungal, candidacidal, Anti-MRSA, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer",50 % Hemolytic at 64 µM,Horse,Synthetic Peptide,Helix,NA,CCCCCSCHHHHHHHHCSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
13968,39204443,2024,FLSLIPKAIKAVSALAKKL,FLSLIPKAIKAVSALAKKL,PSTO2 SR (Phylloseptin-TO2 analog),Free,Free,Linear,L,None,19,"Antibacterial, Antifungal, candidacidal, Anti-MRSA, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer",50 % Hemolytic at 64 µM,Horse,Synthetic Peptide,Helix,NA,CCCGGGGHHHHHHHHTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
13969,39204443,2024,FLSLIPKAIKAVKALAKKL,FLSLIPKAIKAVKALAKKL,PSTO2 SR2 (Phylloseptin-TO2 analog),Free,Free,Linear,L,None,19,"Antibacterial, Antifungal, candidacidal, Anti-MRSA, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer",50 % Hemolytic at 32 µM,Horse,Synthetic Peptide,Helix,NA,CCCSSTHHHHHHHHHHTSSSCSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
13974,39345903,2024,FFPIVAGVAAKVLKKIFCTISKKC,FFPIVAGVAAKVLKKIFCTISKKC,"Brevinin-1pl (natural AMPs; frog, amphibians, animals; XXU; 1S=S, UCSS1a; BBL)",Free,Free,Linear,L,None,24,"Antibacterial, Anticancer, Anti-MRSA, Hemolytic",50 % Hemolytic at 37.64 µM,Horse,"Skin Secretions, The Northern Leopard Frog, Rana Pipiens, North America",Helix,NA,CHHHHHHHHTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)CC)[C@@H](C)O
13978,39427973,2025,FLPFLGKLFSGIF,FLPFLGKLFSGIF{ct:Amid},Temporin-PMb,Amidation,Free,Linear,L,None,13,"Antibacterial, Hemolytic, Anticancer",50 % Hemolytic at 32-64 µM,Human,"Skin Secretion, The Amazon River Frog, Lithobates Palmipes (Ranidae), Brazil, South America",NA,NA,CCHHHHHHHTTTC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
13988,32414842,2020,GFPCGESCVYIPCFTAAIGCSCKSKVCYKN,GFPCGESCVYIPCFTAAIGCSCKSKVCYKN,Hyen D,Free,Free,Linear,L,None,30,"Anticancer, Hemolytic",50 % Hemolytic at 24.56 µM,Human,Hybanthus Enneaspermus,NA,NA,NA,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)CN)C(C)C)[C@@H](C)CC)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C
14164,17277458,2007,DCCHNTQLPFIYKTCPEGCNL,DCCHNTQLPFIYKTCPEGCNL,Cardiotoxin-like basic polypeptide ah (CLBPah),Free,Free,Linear,L,None,21,Anticancer,Hemolytic,Rabbit,Naja Atra (Chinese Cobra),NA,NA,CHHHHHHSSSCCSCCCCCSSSCC,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC(=O)O)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)O
5812,25839356,2015,FIHHIIGWISHGVRAIHRAIH,FIHHIIGWISHGVRAIHRAIH{ct:Amid},Gad-1,Amidation,Free,Linear,L,None,21,"Antibacterial Gram-, Anti-cancer",100 % Hemolysis at 100 µM,Human,Atlantic Cod (Gadus Morhua),α-Helical,NA,CCSHHHHSCTTTSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O
5813,25839356,2015,FIHHIIGWISHGVRAIHRAIH,FIHHIIGWISHGVRAIHRAIH{ct:Amid},Gad-1,Amidation,Free,Linear,L,None,21,"Antibacterial Gram-, Anti-cancer",100 % Hemolysis at 200 µM,Human,Atlantic Cod (Gadus Morhua),α-Helical,NA,CCSHHHHSCTTTSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O
5814,25839356,2015,FIHHIIGWISHGVRAIHRAIH,FIHHIIGWISHGVRAIHRAIH{ct:Amid},Gad-1,Amidation,Free,Linear,L,None,21,"Antibacterial Gram-, Anti-cancer",100 % Hemolysis at 400 µM,Human,Atlantic Cod (Gadus Morhua),α-Helical,NA,CCSHHHHSCTTTSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O
5815,25839356,2015,FLHHIVGLIHHGLSLFGDR,FLHHIVGLIHHGLSLFGDR{ct:Amid},Gad-2,Amidation,Free,Linear,L,None,21,"Antibacterial Gram-, Anti-cancer",50 % Hemolysis at 56 µM,Human,Atlantic Cod (Gadus Morhua),α-Helical,NA,CCCTTTCCTTTCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
5816,25839356,2015,FLHHIVGLIHHGLSLFGDR,FLHHIVGLIHHGLSLFGDR{ct:Amid},Gad-2,Amidation,Free,Linear,L,None,21,"Antibacterial Gram-, Anti-cancer",<90 % Hemolysis at 100 µM,Human,Atlantic Cod (Gadus Morhua),α-Helical,NA,CCCTTTCCTTTCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
5817,25839356,2015,FLHHIVGLIHHGLSLFGDR,FLHHIVGLIHHGLSLFGDR{ct:Amid},Gad-2,Amidation,Free,Linear,L,None,21,"Antibacterial Gram-, Anti-cancer",100 % Hemolysis at 200 µM,Human,Atlantic Cod (Gadus Morhua),α-Helical,NA,CCCTTTCCTTTCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
5818,25839356,2015,FLHHIVGLIHHGLSLFGDR,FLHHIVGLIHHGLSLFGDR{ct:Amid},Gad-2,Amidation,Free,Linear,L,None,21,"Antibacterial Gram-, Anti-cancer",100 % Hemolysis at 400 µM,Human,Atlantic Cod (Gadus Morhua),α-Helical,NA,CCCTTTCCTTTCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
5968,25462264,2015,VKRFKKFFRKLKKSV,VKRFKKFFRKLKKSV{ct:Amid},B1,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,Derivative Of Cathelicidin-Bf15 (Bf-15),α-Helical,Low hemolytic,CHHHHHHHHHHTTCC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)O)C(C)C
5969,25462264,2015,VKRFKKFFRKLKKAV,VKRFKKFFRKLKKAV{ct:Amid},B1-Ala,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CHHHHHHHHHHTTCC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)O)C(C)C
5970,25462264,2015,VKRFKKFFRKLKKVV,VKRFKKFFRKLKKVV{ct:Amid},B1-Val,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CTTTHHHHHHHTTTC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)C(C)C
5971,25462264,2015,VKRFKKFFRKLKKLV,VKRFKKFFRKLKKLV{ct:Amid},B1-Leu,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CTTTHHHHHHHTTTC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)O)C(C)C
5972,25462264,2015,VKRFKKFFRKLKKFV,VKRFKKFFRKLKKFV{ct:Amid},B1-Phe,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CHHHHHHHHHHTTCC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)O)C(C)C
5973,25462264,2015,VKRFKKFFRKLKKGV,VKRFKKFFRKLKKGV{ct:Amid},B1-Gly,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CTTHHHHHHHHTTTC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)O)C(C)C
5974,25462264,2015,VKRFKKFFRKLKKQV,VKRFKKFFRKLKKQV{ct:Amid},B1-Gln,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CHHHHHHHHHHHHHC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)O)C(C)C
5975,25462264,2015,VKRFKKFFRKLKKTV,VKRFKKFFRKLKKTV{ct:Amid},B1-Thr,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CHHHHHHHHHHGGGC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)[C@@H](C)O
5976,25462264,2015,VKRFKKFFRKLKKKV,VKRFKKFFRKLKKKV{ct:Amid},B1-Lys,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CTTTHHHHHHHTTCC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)O)C(C)C
5977,25462264,2015,VKRFKKFFRKLKKRV,VKRFKKFFRKLKKRV{ct:Amid},B1-Arg,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CHHHHHHHHHHTTTC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)O)C(C)C
5978,25462264,2015,VKRFKKFFRKLKKHV,VKRFKKFFRKLKKHV{ct:Amid},B1-His,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",<10 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CHHHHHHHHHHTCC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](C(=O)O)C(C)C
5979,25462264,2015,VKRFKKFFRKLKKDV,VKRFKKFFRKLKKDV{ct:Amid},B1-Asp,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CTTTTTHHHHTTCCC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)O)C(C)C
5980,25462264,2015,VKRFKKFFRKLKKEV,VKRFKKFFRKLKKEV{ct:Amid},B1-Glu,Amidation,Free,Linear,L,None,15,"Anti-cancer, Anti-migratory",5 % Hemolysis at 160 µM,Rabbit,B1 Analog,α-Helical,Low hemolytic,CHHHHHHHHHHTTCC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)O)C(C)C
10371,31199859,2019,FIGAIARLLSKIF,FIGAIARLLSKIF,BmKn-2,Free,Free,Linear,L,None,13,"Antimicrobial, Anti-cancer, Antibiofilm",100 % Hemolysis at 800 µM,Sheep,Scorpion Mesobuthus Martensii Karsch,α-Helix,NA,CCSCCHHHHHHHHHHHHHHHHHHHHHTSCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)CC
11098,32437150,2020,GIPCGESCVYIPCITAALGCSCKSKVCYRN,GIPCGESCVYIPCITAALGCSCKSKVCYRN{cyc:N-C},viar 1,Free,Free,Cyclic,L,None,30,Anti-cancer,50 % Hemolysis at 11.1 ± 0.02 µM,Human,Plant Viola Arcuata,α-Helical,Low hemolytic,CCCSCCSSSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C)[C@@H](C)O
11099,32437150,2020,GIPCGESCVWIPCISAAIGCSCKSKVCYRN,GIPCGESCVWIPCISAAIGCSCKSKVCYRN{cyc:N-C},cO13,Free,Free,Cyclic,L,None,30,Anti-cancer,50 % Hemolysis at 14.9 ± 0.01 µM,Human,Plant Viola Arcuata,α-Helical,Low hemolytic,NA,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C
11100,32437150,2020,GLPVCGETCVGGTCNTPGCSCSWPVCTRN,GLPVCGETCVGGTCNTPGCSCSWPVCTRN{cyc:N-C},kalata S,Free,Free,Cyclic,L,None,29,Anti-cancer,50 % Hemolysis at ≥50 µM,Human,Plant Viola Arcuata,NA,NA,NA,CC(C)C[C@H](NC(=O)CN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C
11506,32872343,2020,SALRGCWTFSIPPKPCL,SALRGCWTFSIPPKPCL{ct:Amid},F-SL,Amidation,Free,Linear,L,None,17,"Antimicrobial, Anti-Cancer",≥10 % Hemolysis at 512 µM,Horse,Sl-Bbi Analogues,"NH4AC = β-Sheet and Random coil, 50%TFE/NH4AC = β-Sheet and Random coil",Low hemolytic,CTHHHHHHHHHHTSCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CO)[C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O
11849,33676184,2021,KWKLFKKIKFLHSAKKF,KWKLFKKIKFLHSAKKF,CE-MA,Free,Free,Linear,L,None,17,"Antibacterial, Antiviral, Antiparasitic, Antifungal, Anti-cancer",>20 % Hemolysis at 500 μg/ml,Human,Synthetic Peptide Consisting Of Cecropin A And Magenin B,α-Helix,NA,CTHHHHGGGGCCCTTCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
13759,36364155,2022,PTECQVGTTCVESS,PTECQVGTTCVESS{nt:Amid},PS14,Free,Amidation,Linear,L,None,14,"Anti-cancer, Anti-inflammatory",25.45 ± 1 % Hemolysis at 5 µM,Human,Aphanomyces Invadans,NA,NA,CCCSHHHHTTTSCSCHHHHHHTC,CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)C(C)C)[C@@H](C)O)[C@@H](C)O
13760,36364155,2022,PTECQVGTTCVESS,PTECQVGTTCVESS{nt:Amid},PS14,Free,Amidation,Linear,L,None,14,"Anti-cancer, Anti-inflammatory",39.21 ± 1.5 % Hemolysis at 10 µM,Human,Aphanomyces Invadans,NA,NA,NA,CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)C(C)C)[C@@H](C)O)[C@@H](C)O
13761,36364155,2022,PTECQVGTTCVESS,PTECQVGTTCVESS{nt:Amid},PS14,Free,Amidation,Linear,L,None,14,"Anti-cancer, Anti-inflammatory",49.10 ± 1.89 % Hemolysis at 15 µM,Human,Aphanomyces Invadans,NA,NA,CCSSSCCSSSCSBCTTSSCCSSSSSSCCBCC,CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)C(C)C)[C@@H](C)O)[C@@H](C)O
13762,36364155,2022,PTECQVGTTCVESS,PTECQVGTTCVESS{nt:Amid},PS14,Free,Amidation,Linear,L,None,14,"Anti-cancer, Anti-inflammatory",69 ± 1.3 % Hemolysis at 20 µM,Human,Aphanomyces Invadans,NA,NA,NA,CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)C(C)C)[C@@H](C)O)[C@@H](C)O
13763,36364155,2022,PTECQVGTTCVESS,PTECQVGTTCVESS{nt:Amid},PS14,Free,Amidation,Linear,L,None,14,"Anti-cancer, Anti-inflammatory",77 ± 2.8 % Hemolysis at 25 µM,Human,Aphanomyces Invadans,NA,NA,NA,CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)C(C)C)[C@@H](C)O)[C@@H](C)O
2317,14514057,2003,KWKLFKKIGIGKFLHSAKKF,KWKLFKKIGIGKFLHSAKKF{ct:Amid},CA-MA,Amidation,Free,Linear,L,None,20,Antibacterial and Antitumor,0% Hemolysis at 100 µM (non-hemolytic),Human,Synthetic peptide,NA,Non-hemolytic,CCCCCCCCSSGGGSSSSCC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
2318,14514057,2003,KWKKLLKKPLLKKLLKKL,KWKKLLKKPLLKKLLKKL{ct:Amid},CA-MA analogue P5,Amidation,Free,Linear,L,None,18,Antibacterial and Antitumor,0% Hemolysis at 100 µM (non-hemolytic),Human,Synthetic peptide,NA,Non-hemolytic,CHHHHTHHHHHHHHGGGC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)C(=O)O
2319,14514057,2003,KWKLKPLLKKLLKKL,KWKLKPLLKKLLKKL{ct:Amid},P6,Amidation,Free,Linear,L,None,15,Antibacterial and Antitumor,0% Hemolysis at 100 µM (non-hemolytic),Human,Synthetic peptide,NA,Non-hemolytic,CCCCGGGHHHHTTTC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)C(=O)O
2320,14514057,2003,KWKKLLKKPLKLKL,KWKKLLKKPLKLKL{ct:Amid},P7,Amidation,Free,Linear,L,None,14,Antibacterial and Antitumor,0% Hemolysis at 100 µM (non-hemolytic),Human,Synthetic peptide,NA,Non-hemolytic,CTHHHHTSCSCCCC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)C(=O)O
2321,14514057,2003,KPLLKKLLKKL,KPLLKKLLKKL{ct:Amid},P8,Amidation,Free,Linear,L,None,11,Antibacterial and Antitumor,0% Hemolysis at 100 µM (non-hemolytic),Human,Synthetic peptide,NA,Non-hemolytic,CTTHHHHGGGC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN)C(=O)O
2322,14514057,2003,KLLKKPLKLKL,KLLKKPLKLKL{ct:Amid},P9,Amidation,Free,Linear,L,None,11,Antibacterial and Antitumor,0% Hemolysis at 100 µM (non-hemolytic),Human,Synthetic peptide,NA,Non-hemolytic,CGGGTGGGCCC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)C(=O)O
2964,21955251,2011,GIIKKI,GIIKKI{ct:Amid},G(IIKK)I,Amidation,Free,Linear,L,None,6,Antimicrobial and Antitumor,Non-hemolytic up to 250 µM,Human,Synthetic peptides,NA,Non-hemolytic,CCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)C(=O)O
2965,21955251,2011,GIIKKIIKKI,GIIKKIIKKI{ct:Amid},G(IIKK)2I,Amidation,Free,Linear,L,None,10,Antimicrobial and Antitumor,Non-hemolytic up to 250 µM,Human,Synthetic peptides,NA,Non-hemolytic,CTHHHHTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(=O)O
2966,21955251,2011,GIIKKIIKKIIKKI,GIIKKIIKKIIKKI{ct:Amid},G(IIKK)3I,Amidation,Free,Linear,L,None,14,Antimicrobial and Antitumor,EC50 >250 µM,Human,Synthetic peptides,NA,NA,CGGGGTGGGTTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(=O)O
2967,21955251,2011,GIIKKIIKKIIKKIIKKI,GIIKKIIKKIIKKIIKKI{ct:Amid},G(IIKK)4I,Amidation,Free,Linear,L,None,18,Antimicrobial and Antitumor,EC50 = 41±2 µM,Human,Synthetic peptides,NA,NA,CGGGGTTHHHHHHHGGGC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C(=O)O
5126,25241629,2014,LKLSPKTKDTLKKVLKGAIKGAIAIASMA,LKLSPKTKDTLKKVLKGAIKGAIAIASMA{ct:Amid},Hymenochirin-1Pa,Amidation,Free,Linear,L,None,29,"Antimicrobial, Antitumor",50 % Hemolysis at 162 ± 13 µM,Human,Skin Secretions Ofthe Frog Pseudhymenochirus Merlini,α-Helix,NA,CCCCCCCGGGHHHHSTTTSSSSCCCCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)O
5127,25241629,2014,LKLSPKTKKTLKKVLKGAIKGAIAIASMA,LKLSPKTKKTLKKVLKGAIKGAIAIASMA{ct:Amid},[D9K]Hymenochirin-1Pa,Amidation,Free,Linear,L,None,29,"Antimicrobial, Antitumor",50 % Hemolysis at 192 ± 21 µM,Human,"Analog Of Hymenochirin-1Pa, Skin Secretions Ofthe Frog Pseudhymenochirus Merlini",α-Helix,NA,CCCCSSCTTTGGGTTTTTCCCCSSSCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)O
5128,25241629,2014,LKLSPKTKkTLKKVLKGAIKGAIAIASMA,LKLSPKTKK{d}TLKKVLKGAIKGAIAIASMA{ct:Amid},[D9k]Hymenochirin-1Pa,Amidation,Free,Linear,Mix,lowercase letters correspond to D-amino acids,29,"Antimicrobial, Antitumor",50 % Hemolysis at >400 µM,Human,"Analog Of Hymenochirin-1Pa, Skin Secretions Ofthe Frog Pseudhymenochirus Merlini",α-Helix,NA,CCCCSSCTTTGGGTTTTTCCCCSSSCCCC,NA
5129,25447194,2014,IKIPSFFRNILKKVGKEAVSLIAGALKQS,IKIPSFFRNILKKVGKEAVSLIAGALKQS,Pseudhymenochirin-1Pb(Ps-1Pb),Free,Free,Linear,L,None,29,"Antimicrobial, Antitumor",50 % Hemolysis at 28 ± 2 µM,Human,Skin Secretions Of The Frog Pseudhymenochirus Merlini,α-Helix,NA,CCSHHHHHHHTTHHHHHHHHHHHHHHTTC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)O)[C@@H](C)CC)C(C)C)C(C)C)[C@@H](C)CC)[C@@H](C)CC
5130,25447194,2014,GIFPIFAKLLGKVIKVASSLISKGRTE,GIFPIFAKLLGKVIKVASSLISKGRTE,(Pseudhymenochirin-2Pa)Ps-2Pa,Free,Free,Linear,L,None,27,"Antimicrobial, Antitumor",50 % Hemolysis at 6.2 ± 1.0 µM,Human,Skin Secretions Of The Frog Pseudhymenochirus Merlini,α-Helix,NA,CCCHHHHHHHHHHHHHHHHHHTTCCCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(C)C)[C@@H](C)CC
6355,27197902,2016,GLRRALLRLLRSLRRLLLRA,GLRRALLRLLRSLRRLLLRA,P7,Free,Free,Linear,L,None,20,"Antibacterial, Antitumor, Antifungal",0 % Hemolysis at 4-32 µM,Mouse,Cell-Penetrating Peptide Pptg20,α-Helix,Non-hemolytic,CHHHHHHHHHHHHHHHHSCC,CC(C)C[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)O
6534,27907988,2016,KRIVQRIKDFLR,KRIVQRIKDFLR{ct:Amid},KR12,Amidation,Free,Linear,L,None,12,"Antimicrobial, Antitumor",30 % Hemolysis at 0.78 μg/ml,Rabbit,Cathelicidin Ll-37,α-Helix,NA,CGGGTTCTTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
6535,27907988,2016,KRIVQRIKDFLR,KRIVQRIKDFLR{ct:Amid},KR12,Amidation,Free,Linear,L,None,12,"Antimicrobial, Antitumor",<45 % Hemolysis at 7.8 μg/ml,Rabbit,Cathelicidin Ll-37,α-Helix,NA,CGGGTTCTTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
6536,27907988,2016,KRIVQRIKDFLR,KRIVQRIKDFLR{ct:Amid},KR12,Amidation,Free,Linear,L,None,12,"Antimicrobial, Antitumor",<45 % Hemolysis at 15.6 μg/ml,Rabbit,Cathelicidin Ll-37,α-Helix,NA,CGGGTTCTTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
6537,27907988,2016,KRIVQRIKDFLR,KRIVQRIKDFLR{ct:Amid},KR12,Amidation,Free,Linear,L,None,12,"Antimicrobial, Antitumor",70 % Hemolysis at 31.2 μg/ml,Rabbit,Cathelicidin Ll-37,α-Helix,NA,CGGGTTCTTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
6538,27907988,2016,KRIVQRIKDFLR,KRIVQRIKDFLR{ct:Amid},KR12,Amidation,Free,Linear,L,None,12,"Antimicrobial, Antitumor",70 % Hemolysis at 62.5 μg/ml,Rabbit,Cathelicidin Ll-37,α-Helix,NA,CGGGTTCTTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
6539,27907988,2016,KRIVQRIKDFLR,KRIVQRIKDFLR{ct:Amid},KR12,Amidation,Free,Linear,L,None,12,"Antimicrobial, Antitumor",73 % Hemolysis at 125 μg/ml,Rabbit,Cathelicidin Ll-37,α-Helix,NA,CGGGTTCTTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
8052,37746048,2023,DASTKKLSECLRRIGDELDS,DASTKKLSECLRRIGDELDS,BHP,Free,Free,Linear,L,None,20,Antitumor,0 % Hemolysis at 3-200 μg/ml,Human,Synthetic,NA,Non-hemolytic,CCCCCCCSSCSSCCTTCCCTHHHHTTTC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(=O)O)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O
9433,29760411,2018,A{d}-L/I-L/I-L/I-R{d}-L/I-L/I-V{d}-K-L/I-T-L/I-S{d}-K-K,A{d}-L/I-L/I-L/I-R{d}-L/I-L/I-V{d}-K-L/I-T-L/I-S{d}-K-K{cyc},Paenialvin-A,Free,Free,Bicyclic,Mix,None,23,"Antibacterial,Antitumor",3.61 % Hemolysis at 50 μg/ml,Rabbit,Bacteria Paenibacillus Alvei Dsm 29,NA,Non-hemolytic,NA,NA
9935,30794440,2019,RQCKAESNTFTGICIAKPPCRQACIREKFTDGHCSKVLRRCLCTKRC,RQCKAESNTFTGICIAKPPCRQACIREKFTDGHCSKVLRRCLCTKRC,NoD173,Free,Free,Linear,L,None,47,"Antitumor, Antiproliferative, Antimicrobial",~12 % Hemolysis at 100 µM,Human,Plant Nicotiana Occidentalis Defensin 173 (Nod173),single α-Helix braced by 3 disulfide bonds to a Triple-Stranded antiparallel b-Sheet,Low hemolytic,CCSCCCHHHHC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC
10586,31062442,2019,LKKLLKLLKKLLKL,LKKLLKLLKKLLKL{ct:Amid},LK,Amidation,Free,Linear,L,None,14,Antitumor,60 % Hemolysis at 200 µM,Mouse,Synthetic Cell‐Penetrating Peptides (Cpps),"TFE/water(pH = 7.4, pH = 6) = α-Helix",NA,CCEEEETTEEEECC,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(C)C)C(=O)O
10587,31062442,2019,LHHLLHHLHHLLHH,LHHLLHHLHHLLHH{ct:Amid},LH,Amidation,Free,Linear,L,None,14,Antitumor,0 % Hemolysis at 200 µM,Mouse,Synthetic Cell‐Penetrating Peptides (Cpps),"TFE/water(pH = 7.4, pH = 6) = α-Helix",Non-hemolytic,CCHHHHHHHHHHHHHHHHHHHHHHHHHHTTTTTCCCC,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O
11609,33194795,2020,RFRLPFRRPPIRIHPPPFYPPFRRFL,RFRLPFRRPPIRIHPPPFYPPFRRFL{ct:Amid},ChBac3.4-NH2(caprine proline-rich bactenecin),Amidation,Free,Linear,L,None,26,"Antitumor, Antimicrobial, Antibiofilm",25 ± 2 % Hemolysis at 64 µM,Human,Domestic Goat Capra Hircus,NA,NA,CCCCCCCCSCCCCCCTTSCSSSSCCCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)CC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)O
11612,33194795,2020,RFRLPFRRIHPPPFVRIHPPPFYRRFL,RFRLPFRRIHPPPFVRIHPPPFYRRFL,ChBac3.4-1-COOH,Free,Free,Linear,L,None,27,"Antitumor, Antibacterial",<5 % Hemolysis at 64 µM,Human,Chbac3.4 Full-Lenght Variants,NA,Low hemolytic,CCCCSCSSCCSCCSSSCC,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)O
11742,33442249,2021,RADARADARADARADA,RADARADARADARADA{nt:Acet}{ct:Amid},RADA16-I,Amidation,Acetylation,Linear,L,None,16,"Antitumor, self-assembling peptide",<5 % Hemolysis at 9 mg/mL,Rabbit,Synthetic Pepetide,NA,NA,NA,C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)O
4369,24185042,2013,IKLSPETKDNLKKVLKGAIKGAIAVAKMV,IKLSPETKDNLKKVLKGAIKGAIAVAKMV{ct:Amid},Hymenochirin-1B,Amidation,Free,Linear,L,None,29,Anti-tumor,50 % Hemolysis at 213 ± 18 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CCCCCCCSCHHHHHHTTTBCCSSCSBSCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)O)C(C)C)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)O
4370,24185042,2013,LKIPGFVKDTLKKVAKGIFSAVAGAMTPS,LKIPGFVKDTLKKVAKGIFSAVAGAMTPS,Hymenochirin-2B,Free,Free,Linear,L,None,29,Anti-tumor,50 % Hemolysis at 210 ± 21 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CCSCCTHHHHHHHHHHHHHTTTSSCCCCC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(C)C)[C@@H](C)CC)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O)[C@@H](C)O)C(C)C
4371,24185042,2013,IKIPAVVKDTLKKVAKGVLSAVAGALTQ,IKIPAVVKDTLKKVAKGVLSAVAGALTQ,Hymenochirin-3B,Free,Free,Linear,L,None,29,Anti-tumor,50 % Hemolysis at >400 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CCCCTTHHHHHHHHHHHHHHHHHHHHTC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)O)C(C)C)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C)[C@@H](C)CC
4372,24185042,2013,IKIPAFVKDTLKKVAKGVISAVAGALTQ,IKIPAFVKDTLKKVAKGVISAVAGALTQ,Hymenochirin-4B,Free,Free,Linear,L,None,28,Anti-tumor,50 % Hemolysis at 158 ± 6 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CCCCTTHHHHHHHHTTGGGSSTTCTTTC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)CC
4373,24185042,2013,IKLSKETKDNLKKVLKGAIKGAIAVAKMV,IKLSKETKDNLKKVLKGAIKGAIAVAKMV{ct:Amid},[P5K]-1B,Amidation,Free,Linear,L,None,29,Anti-tumor,50 % Hemolysis at 205 ± 15 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CCCCCCCSCHHHHHSCTTBCCSSSCBCCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)O)C(C)C)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)O
4374,24185042,2013,IKLSPKTKDNLKKVLKGAIKGAIAVAKMV,IKLSPKTKDNLKKVLKGAIKGAIAVAKMV{ct:Amid},[E6K]-1B,Amidation,Free,Linear,L,None,29,Anti-tumor,50 % Hemolysis at 186 ± 4 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CCCCTTCSCCSHHHHTTCBCCSSSSBCCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)O)C(C)C)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)O
4375,24185042,2013,IKLSPETKKNLKKVLKGAIKGAIAVAKMV,IKLSPETKKNLKKVLKGAIKGAIAVAKMV{ct:Amid},[D9K]-1B,Amidation,Free,Linear,L,None,29,Anti-tumor,50 % Hemolysis at 174 ± 12 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CCCCCCCTTCCGGGGGTTBCCSTTSBSCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)O)C(C)C)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)O
4376,24185042,2013,IKLSKKTKDNLKKVLKGAIKGAIAVAKMV,IKLSKKTKDNLKKVLKGAIKGAIAVAKMV{ct:Amid},"[P5K,E6K]-1B",Amidation,Free,Linear,L,None,29,Anti-tumor,50 % Hemolysis at 137 ± 11 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CCSSCCCHHHHHGGGGTTBCTTSCSBSCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)O)C(C)C)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)O
4377,24185042,2013,IKLSKETKKNLKKVLKGAIKGAIAVAKMV,IKLSKETKKNLKKVLKGAIKGAIAVAKMV{ct:Amid},"[P5K,D9K]-1B",Amidation,Free,Linear,L,None,29,Anti-tumor,50 % Hemolysis at 127 ± 9 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CTTSHHHHHHHGGGGGTTBCTTSSSBSCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)O)C(C)C)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)O
4378,24185042,2013,IKLSPKTKKNLKKVLKGAIKGAIAVAKMV,IKLSPKTKKNLKKVLKGAIKGAIAVAKMV{ct:Amid},"[E6K,D9K]-1B",Amidation,Free,Linear,L,None,29,Anti-tumor,50 % Hemolysis at 85 ± 5 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CTTSSSSHHHHGGGHHHHBCSSTTSBSCC,CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)O)C(C)C)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)O
4379,24185042,2013,IKLSPkTKDNLKKVLKGAIKGAIAVAKMV,IKLSPK{d}TKDNLKKVLKGAIKGAIAVAKMV{ct:Amid},[E6k]-1B,Amidation,Free,Linear,Mix,lowercase letters correspond to D-amino acids,29,Anti-tumor,50 % Hemolysis at 188 ± 8 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CCCCTTCSCCSHHHHTTCBCCSSSSBCCC,NA
4380,24185042,2013,IKLSPETKkNLKKVLKGAIKGAIAVAKMV,IKLSPETKK{d}NLKKVLKGAIKGAIAVAKMV{ct:Amid},[D9k]-1B,Amidation,Free,Linear,Mix,lowercase letters correspond to D-amino acids,29,Anti-tumor,50 % Hemolysis at >400 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CCCCCCCTTCCGGGGGTTBCCSTTSBSCC,NA
4381,24185042,2013,IKLSPkTKkNLKKVLKGAIKGAIAVAKMV,IKLSPK{d}TKK{d}NLKKVLKGAIKGAIAVAKMV{ct:Amid},"[E6k,D9k]-1B",Amidation,Free,Linear,Mix,lowercase letters correspond to D-amino acids,29,Anti-tumor,50 % Hemolysis at 302 ± 21 µM,Human,Congo Clawed Frog Hymenochirus Boettgeri,α-Helix,NA,CTTSSSSHHHHGGGHHHHBCSSTTSBSCC,NA
11061,32582642,2020,ALWKDMLKGIGKLAGKAALGAVKTLV,ALWKDMLKGIGKLAGKAALGAVKTLV{ct:Amid},Dermaseptin-PP,Amidation,Free,Linear,L,None,26,"Antimicrobial, Anti-tumor",<20 % Hemolysis at 16 µM,Horse,Frog Phyllomedusa Palliata,50% TFE-10 mmol/L NH4Ac solution (MME) = α-Helical,NA,CTTHHHHHHHHHHTC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)O)C(C)C)[C@@H](C)O)C(C)C
11062,32582642,2020,ALWKDMLKGIGKLAGKAALGAVKTLV,ALWKDMLKGIGKLAGKAALGAVKTLV{ct:Amid},Dermaseptin-PP,Amidation,Free,Linear,L,None,26,"Antimicrobial, Anti-tumor",50 % Hemolysis at 38.77 µM,Horse,Frog Phyllomedusa Palliata,50% TFE-10 mmol/L NH4Ac solution (MME) = α-Helical,NA,CCHHHHHHHHHHTC,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)O)C(C)C)[C@@H](C)O)C(C)C
12196,34461456,2021,gigavlkvlttglpaliswikrkrqqc,G{d}I{d}G{d}A{d}V{d}L{d}K{d}V{d}L{d}T{d}T{d}G{d}L{d}P{d}A{d}L{d}I{d}S{d}W{d}I{d}K{d}R{d}K{d}R{d}Q{d}Q{d}C{d},D-melittin,Free,Free,Linear,L,None,27,Anti-tumor,50 % Hemolysis at 14.8 µM (pH 5.4),Human,Honeybee Venom,NA,NA,CCCSCCTTSCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C
12197,34461456,2021,gigavlkvlttglpaliswikrkrqqc,G{d}I{d}G{d}A{d}V{d}L{d}K{d}V{d}L{d}T{d}T{d}G{d}L{d}P{d}A{d}L{d}I{d}S{d}W{d}I{d}K{d}R{d}K{d}R{d}Q{d}Q{d}C{d},D-melittin,Free,Free,Linear,L,None,27,Anti-tumor,50 % Hemolysis at 8.5 µM (pH 6.4),Human,Honeybee Venom,NA,NA,CCHHHHHHHHTTCC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C
12198,34461456,2021,gigavlkvlttglpaliswikrkrqqc,G{d}I{d}G{d}A{d}V{d}L{d}K{d}V{d}L{d}T{d}T{d}G{d}L{d}P{d}A{d}L{d}I{d}S{d}W{d}I{d}K{d}R{d}K{d}R{d}Q{d}Q{d}C{d},D-melittin,Free,Free,Linear,L,None,27,Anti-tumor,50 % Hemolysis at 3.3 µM (pH 7.4),Human,Honeybee Venom,NA,NA,CCCCCCBCTTSCBC,CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C